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FIVE tO 10% of the human population have a
disorder of the respiratory tract called ’asthma’. It
has been known as a potentially dangerous
disease for over 2000 years, as it was already
described by Hippocrates and recognized as a
disease entity by Egyptian and Hebrew physi-
cians. At the beginning of this decade, there has
been a fundamental change in asthma manage-
ment. The emphasis has shifted from symptom
relief with bronchodilator therapies (e.g. 2-
agonists) to a much earlier introduction of anti-
inflammatory treatment (e.g. corticosteroids).
Asthma is now recognized to be a chronic inflam-
matory disease of the airways, involving various
inflammatory cells and their mediators. Although
asthma has been the subject of many investiga-
tions, the exact role of the different inflammatory
cells has not been elucidated completely. Many
suggestions have been made and several cells
have been implicated in the pathogenesis of
asthma, such as the eosinophils, the mast cells,
the basophils and the lymphocytes. To date, how-
ever, the relative importance of these cells is not
completely understood. The cell type predomi-
nantly found in the asthmatic lung is the eosino-
phil and the recruitment of these eosinophils can
be seen as a characteristic of asthma. In recent
years much attention is given to the role of the
newly identified chemokines in asthma pathol-
ogy. Chemokines are structurally and functionally
related 8-10 kDa peptides that are the products of
distinct genes clustered on human chromosomes
4 and 17 and can be found at sites of inflamma-
tion. They form a superfamily of proinflamma-
tory mediators that promote the recruitment of
various kinds of leukocytes and lymphocytes. The
chemokine superfamily can be divided into three
subgroups based on overall sequence homology.
Although the chemokines have highly conserved
amino acid sequences, each of the chemokines
binds to and induces the chemotaxis of particular
classes of white blood cells. Certain chemokines
stimulate the recruitment of multiple cell types
including monocytes, lymphocytes, basophils,
and eosinophils, which are important cells in
asthma. Intervention in this process, by the
development of chemokine antagonists, might be
the key to new therapy. In this review we present
an overview of recent developments in the field
of chemokines and their role in inflammations as
reported in literature.
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Introduction
Diseases characterized by airway inflammation,
excessive airway secretion and airway obstruc-
tion affect a substantial proportion of the
population. These diseases include asthma,
(C) 1996 Rapid Science Publishers
chronic bronchitis, bronchiectasis and cystic
fibrosis.
Asthma has been the subject of extensive
research for many years. This is not surprising
as asthma is a frequently occurring disease with
a history of a high morbidity and mortality. Until
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a few years ago the primary symptoms of mast cells and epithelium cells also contribute
asthma were thought to be increased airway to the production of mediators. Some of these
responsiveness and recurrent ’reversible’ airway mediators, e.g. histamine, LTC4, LTD4 and pros-
obstruction. This is shown by the definition of taglandin D2 will cause direct contraction of the
asthma by the American Thoracic Society dating airway smooth muscle, producing a broncho-
from 1987. spasm and thus an airway obstruction. Various
chemotaxins (e.g. LTB4 and chemokines) initiateAsthma is a clinical syndrome characterised by increased
responsiveness of the tracheo-bronchial tree to a variety the inflammatory reaction in the airways by
of stimuli. The major symptoms of asthma are attacks of attracting leukocytes into the area and hence
dyspnea (disorder of breathing), wheezing and cough, preparing for the late-phase reaction.
which may vary from mild and almost undetectable to The second, late-phase occurs in approxi-
severe and unremitting (status asthmaticus). The pri-
mately 50% of the asthmatics (even more inmary physiological manifestation of this hyperrespon-
siveness is variable airway obstruction. This can take the children)6 at a variable time after exposure to
form of spontaneous fluctuations in the severity of the elicting stimulus. This phase is in essence a
obstruction, substantial improvements in the severity of progressing inflammatory reaction and is caused
obstruction followingbronchodilatorsor corticosteroids, by the infiltration of, amongst others, airway
or increased obstruction caused by drugs or other
stimuli obstruction neutrophils and eosinophils. Eosino-
phils especially play an important role in the
The major goal in treatment was to reverse this pathogenesis of asthma.7 Most of the products
airway obstruction, released by these cells have been tested for
At the beginning of this decade, a fundamen- their effects on lung tissue. They all have some
tal change in asthma management took place, effects (extensively reviewed by Barnes8) but
The emphasis has shifted from symptom relief none of them is solely responsible for the
with bronchodilator therapies to a much earlier observed phenomenon in the asthmatic re-
introduction of anti-inflammatory treatments.2 action.9
Based on a growing body of evidence, allergic
as well as intrinsic bronchial asthma have been Inflammatory Cellsdefined as chronic persistent inflammatory dis-
orders. Agreement has been reached that asth- A number of studies have provided information
ma can no longer be seen as an equivalent of on cell populations in bronchoalveolar lavage
bronchospasm and that the absence of reversi- (BAL) fluid in mild, stable asthmatics with
bility of airflow obstruction does not exclude persistent airways hyperresponsiveness and
bronchial asthma. asthma.-12 Common findings in these studies,
Thus, asthma is now recognized to be a as well as in recent examinations of bronchial
chronic inflammatory disease of the airways, mucosal biopsies,1a4 are the presence of in-
involving amongst others mast cells, eosinophils creased numbers of inflammatory cells, such as
and T-lymphocytes. Airway production of che- eosinophils, lymphocytes and mast cells, com-
mokines, cytokines and growth factors in re- pared with normal control subjects with normal
sponse to irritants, infectious agents and airway responsiveness. The eosinophils have
inflammatory mediators also play an important shown signs of activation, as indicated by in-
role in the modulation of acute and chronic creased levels of granular proteins, major basic
airway inflammation.4 Treatment of asthma protein (MBP) and eosinophilic cationic protein
should therefore be based on anti-inflammatory (ECP).15 Both MCP and ECP are cytotoxic for
agents rather than bronchodilators.2 airway epithelium. Azzawi et aL16 have also
The asthmatic attack can be divided in two demonstrated significant increases in the num-
main phases: the immediate- or early-phase ber of activated T-lymphocytes. Mast cells in the
asthmatic response and the delayed- or late- airways mucosa have exhibited various stages of
phase reaction. This division is fairly arbitrary, degranulation,14 suggesting that mediator re-
because in some subjects only one of the lease is an ongoing process in the airways of
phases may be obvious, but it provides a useful stable asthmatics with persistent airway hyper-
basis for discussing the physiopathological responsiveness. These inflammatory cells re-
changes in the bronchi and the mediators that lease a wide variety of mediators, including
are involved.5 The early-phase, i.e. the initial local release of preformed mediators, newly
response, occurs abruptly and is due mainly to synthesized metabolites of arachidonic acid, and
spasm of the bronchial smooth muscle. After a soluble pro-inflammatory proteins including ki-
7challenge with all kinds of stimuli, the alveolar nins and cytokines. Airway epithelial cells
macrophages will be activated and produce participate in local cytokine networks and
mediators. Other primary effector cells, such as regulate inflammatory airway events by synthe-
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sizing and secreting various cytokines that pathophysiology of asthma. Human mast cells
communicate in a paracrine manner with infil- contain tryptase, chymase, carboxypeptidase A,
trating inflammatory cells and structural airway and several acid hydrolases, while basophils
cells. Furthermore, airway epithelial cells repre- contain lysophospholipase.7
sent targets for numerous cytokines that regu-
late the expression of immune and inflam-
matory airway epithelial cell products.
Mediators
Newly synthesized mediators
The non-preformed mediators derived from
basophils, eosinophils, mast cells, and other
sources are also known as the lipid mediators.
Release of inflammatory mediators such as With the exception of platelet activating factor
histamine and products of arachidonic acid (PAF), they are products of arachidonic acid
metabolism has been demonstrated in BAL fluid metabolism through two different pathways.
of patients with asthma. Airway inflammation in The cyclooxygenase pathway is responsible for
asthma is a complex series of events triggered the generation of prostaglandins, prostacyclin,
by inflammatory stimuli interacting with pri- and thromboxane, while the lipoxygenase path-
mary effector cells resident within the airways, way generates leukotrienes and HETES (hydroxy-
Release of inflammatory mediators from these eicosatetraenoic acids). In the 5-1ipoxygenase
cells may in turn recruit and activate other pathway, arachidonic acid undergoes lipoxy-
effector cells or cell-independent systems, with genation to produce leukotriene A4 (LTA4). This
generation of other mediators, thus augmenting is subsequently metabolized to LTB4 or LTC4.
the inflammatory process. These include pre- LTC4 in turn is rapidly metabolized to LTD4 and
formed mediators, such as histamine, mediators LTE4. In physiologic studies the leukotrienes
newly synthesized by basophils or mast cells seem to have about the same range of activities
after antigen stimulation, such as leukotrienes, as does histamine, and levels of leukotrienes
and mediators generated secondarily as a result within the airways are higher in asthma. The
of primary mediator release. An example of the cyclooxygenase enzyme catalyzes the incorpora-
latter is bradykinin, which is generated by the tion of molecular oxygen into the arachidonic
action of kallikrein on serum kininogen. Still acid and promotes ring closure to form the
other mediators are released from actively relatively unstable cyclic endoperoxides PGG2
recruited cells over longer periods of time (e.g. and PGH2. These are converted to the primary
eosinophil granule constituents, cytokines; che- prostaglandins such as PGD2, PGE2, and PGF2.
mokines), and their importance in the immuno- Alternatively, the endoperoxides may also be
pathogenesis of asthma has been inferred based metabolized to prostacyclin (PGI2) or throm-
on their detection within the asthmatic airway, boxane A2. Prostaglandin D2 is the predominant
or following experimental allergen challenge.17 prostanoid generated by mast cells; none is
Inflammatory mediators may have a variety of generated in human basophils.19 A cyclooxygen-
effects on several target cells within the airway ase subtype, cyclooxygenase-2, is induced dur-
and may mimic many of the features found in ing inflammation. Therefore, the prostaglandin
asthma. They may lead to contraction of the production will be increased during inflamma-
airway smooth muscle, either directly or indir- tory processes.
ectly, through the release of other mediators, or Until recently, PAF was thought to be one of
the activation of neural pathway.8 the most important mediators in the pathogen-
esis of asthma. This was because it mimics
many features of asthma and, in addition toPreformed mediators having physiologic activities much like those of
Histamine was the first inflammatory mediator histamine, it also is chemotactic for eosinophils
studied, having been synthesized in 1907 and and other inflammatory cells in vivo.20 How-
studied extensively by Dale and Laidlaw in the ever, it has subsequently been found that other
18years thereafter. Histamine s generated n mediators such as the leukotrienes may have a
basophils and mast cells by the enzymatic similar activity.17
decarboxylation of histidine. Elevations of hista- Other mediators generated subsequent to
mine in BAL fluids have been found in the mast cell and basophil mediator release are the
airways of asthmatics, and the levels increase kinins. Bradykinin has effects similar to the
strikingly within minutes and even many hours tachykinins (neurokinins A and B, substance P).
following antigen challenge. The other pre- When inhaled, it is a potent bronchoconstrictor
formed mediators in human basophils and mast and causes a sensation of dyspnoea similar to
cells have as yet no well defined roles in the asthma. This is probably due to an action on
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sensory nerves within the airways. Levels of
kinins have been found to be elevated in
asthmatic airways and to increase even further
after segmental antigen challenge.17
Other pro-inflammatory proteins
A host of cytokines released by T-lymphocytes
and other cells are pivotal in mediating many
inflammatory responses in allergic diseases in-
cluding asthma. Detectable levels of mRNA for
TNF, IL-1, IL-3, IL-4, IL-5, and GM-CSF has been
reported in biopsies or BAL fluids. A similar but
slightly different panel of cytokine proteins has
also been observed (e.g. IL-2 and IL-6 have also
been detected). The source of these and other
cytokines may include not only T-lymphocytes
but also macrophages, epithelial cells, mast
cells, basophils, and eosinophils.
As mentioned above, eosinophilic inflamma-
tion is a consistent and prominent finding in
asthma. The eosinophil granule proteins (a
second category of pro-inflammatory proteins),
such as eosinophil cationic protein (ECP),
eosinophil peroxidase (EPO), and major basic
protein (MBP), are highly toxic to epithelium
and other pulmonary cells, and inhalation of
MBP can induce hyperreactivity.21
A third category of pro-inflammatory proteins
are the chemokines, a special type of cytokines.
In the remaining sections of this review the
chemokines will be discussed.
Chemokines and Inflammation
Chemokines are structurally and functionally
related 8-10 kDa peptides that are the products
of distinct genes clustered on human chromo-
somes 4 and 17. They are a superfamily of
proinflammatory mediators that promote the
recruitment of various kinds of leukocytes and
lymphocytes32 Chemokines are strongly impli-
cated in a wide range of human acute and
chronic inflammatory diseases, including arthri-
tis, respiratory diseases, and arteriosclerosis.3
Additionally, they may play an important role in
host defense against infections and in wound
healing.
The invasion of the body by pathogenic
organisms triggers a cellular response by the
immune system that leads to the recruitment of
leukocytes. The initial migration of leukocytes
toward the site of infection (chemotaxis) is
mediated by a variety of molecules, called
chemoattractants or chemotaxins.24 The chemo-
attractant is the signal that triggers a complex
sequence of events dependent on interactions
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between adhesion molecules and their comple-
mentary ligands on leukocytes.25
Much of the knowledge concerning leukocyte
chemoattractants originates from use of the
Boyden chamber which measures chemotaxins
in vitro. The invention of the chemotaxis
chamber by Boyden in 1962 allowed in vitro
quantification of leukocyte movements in de-
fined gradients or soluble chemoattractants.26
The first chemoattractant for neutrophils
demonstrated using this system was the comple-
ment fragment C5a. By 1986, the structural and
functional properties of the ’classical’ chemo-
attractants N-formyl-methionyl-leucyl-phenylala-
nine (fMLF), C5a, leukotriene B4, and platelet-
activating factor (PAF) had been extensively
detailed.27
Recently, the number of structurally defined
chemoattractants for leukocytes has greatly in-
creased, largely due to the identification of the
chemokine superfamily.28 The name ’chemo-
kine’ was proposed at the Third International
Symposium of Chemotactic Cytokines at Baden
in 1992. ’Chemokine’ combines the chemoat-
tractant and cytokine properties that have been
identified for many of these peptides. Previous
to this symposium the chemokines were termed
’intercrines’. Immunologists first detected a
member of the intercrine family when Luster et
aL29 in 1985 reported the induction of gene
expression for a peptide homologous to platelet
proteins in interferon gamma (IFN-y) stimulated
macrophages and termed the peptide ’IP-10’.
Subsequently, Yoshimura et aL331 isolated and
identified a novel monocyte cell-derived neutro-
phil chemoattractant, and they were the first to
separate this peptide biochemically from IL-1
and TNF, which were previously considered to
be responsible for this activity. This novel
chemoattractant polypeptide was initially
named ’monocyte-derived neutrophil chemotac-
tic factor’ (MDNCF). Various investigators have
referred to this peptide as a ’neutrophil activat-
ing protein’ (NAP), MDNCE NAE GCE LCF, LAI
and most recently IL-8.28 The fact that the
chemokines have remarkably conserved se-
quences, distinguishes them from the other
chemoattractants and most other cytokines.27
Although the superfamily is defined by struc-
ture, three common functional properties are
also apparent. Firstly, chemokines attract one or
more myeloid cell types in vitro. Secondly, the
production and/or secretion of most chemo-
kines in source cells is induced by pro-inflam-
matory stimuli such as lipopolysaccharide,
tumour necrosis factor-1 (TNF-1) or interleukin-
1 (IL-1). Thirdly, all those chemokines that have
been tested induce inflammatory infiltrates
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when injected intradermally into animals,
although certain species barriers may exist.32
The human chemokine polypeptides are 70-
90 residues in length and have internal disul-
phide bonds, comparable with C3a, C4a, and
C5a. However, the chemokine and complement
fragment sequences are only 15% identical. All
chemokines have four cysteine residues which
form two disulphide bridges,is Traditionally, the
chemokine superfamily has been divided into
two subgroups: CXC (c; C is cysteine and X is
any amino acid) and CC ([), based on the
chromosomal location of the gene, the overall
sequence homology and the disposition of the
first two of the four conserved cysteine residues
(Fig. 1). All known (z chemokines are 25-90%
identical, while all known chemokines are
25-70% identical. Any (z chemokine is 20-30%
identical to any chemokine.
Recently, the discovery of a new protein
suggests that the superfamily may have an
additional branch, the ’C’ (%,) branch. Lympho-
tactin, a molecule isolated from pro-T cells,
clearly lacks the first and third cysteines in the
four cysteine pattern, but shares a large amount
of amino acid similarity at its carboxyl terminus
with CC chemokines (Fig. 1).33 The structural
analysis, chromosomal location and biological
properties of lymphotactin provide strong evi-
dence that this cytokine represents a new class
of chemokine.34, 35
Although the chemokines have highly con-
served amino acid sequences, each of the
chemokines binds to and induces the chemo-
taxis of a particular class of white blood cells.
CXC ((z) chemokines (such as IL-8 and MGSA)
stimulate predominantly neutrophils, except for
platelet factor 4 (PF-4) and y-interferon induci-
ble protein (yIP-lO). CC () chemokines (such
as MIP-I(, MCP-1 and RANTES) on the other
hand, do not affect neutrophils but stimulate
multiple cell types including monocles, lym-
phocytes, basophils, and eosinophils.36 The C
(%,) chemokine lymphotactin mainly attracts
lymphocytes.
There are probably more structural distinc-
tions to be made, which may explain/enlighten
chemokine function. Within the CXC group, the
majority of the known proteins contain the
amino acid motif Glu-Leu-Arg-Cys-Xaa-Cys
(ELRCXC or ELR) at the amino terminal region.
These amino acids are absent in certain mem-
CXC Chemokines
IL-8
NAP-2
ENA-78
GRO-a
GRO-b
GRO-c
PF4
IP-10
MIG
SAKELRCQCIKTYSKPFHPKFIKELRVIESGPHCANTEIIVKLSD.GRELCLDPKENWVQRVVEKFLKRAENS
AELRCMCIKTTSG.IHPKNIQSLEVIGKGTHCNQVEVIATLKD.GRKICLDPDAPRIKKIVQKKLAGDESAD
AGPAAALRELRCCLQTTQG.HPKMSNLQFAGPQCSKVEASLKN.GKECLDPEAPFLKKVQKLDGGNKEN
ASVATELRCQCLQTLQG.IHPKNIQSVNVKSPGPHCAQTEVIATLKN.GRKACLNPASPIVKKIIEKMLNSDKSN
APLATELRCQCLQTLQG.IHLKNIQSVKVKSPGPHCAQTEVIATLKN.GQKACLNPASPMVKKIIEKMLKNGKSN
ASVVTELRCQCLQTLQG.IHLKNIQSVNVRSPGPHCAQTEVIATLKN.GKKACLNPASPMVQKIIEKILNKGSTN
EAEEDGDLQCLCVKTTSQ.VRPRHITSLEVIKAGPHCPTAQLIATLKN.GRKICLDLQAPLYKKIIKKLLES
VPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKEMSKRSP
TPVVRKGRCSCISTNQGTIHLQSLKDLKQFAPSPSCEKIEIIATLKN.GVQTCLNPDSADVKELIKKWEKQVSQ
CC Chemokines
RAI’,FIT_
I309
MIP-lct
MIP-I[
MCP-1
MCP-2
MCP-3
SPYSSDT.TPC.CFAYIARPLPRAHIKEYFYTSGK..CSNPAVVFVTRKN.RQVCANPEKKWVREYINSLEMS
SKSMQVPFSRC.CFSFAEQEIPLRAILCYRNTSSI..CSNEGLIFKLKRG.KEACALDTVGWVQRHRKMLRHCPSKRK
ASLAADTPTAC.CFSYTSRQIPQNFIADYFETSSQ..CSKPGVIFLTKRS.RQVCADPSEEWVQKYVSDLELSA
APMGSDPPTAC.CFSYTARKLPRNFVVDYYETSSL..CSQPAVVFQTKRS.KQVCADPSESWVQEYVYDLELN
QPDAINAPVTC.CYNFTNRKISVQRLASYRRITSSK.CPKEAVIFKTIVA.KEICADPKQKWVQDSMDHLDKQTQTPKT
QPDSVSIPITC.CFNVINRKIPIQRLESYTRITNIQ.CPKEAVIFKTKRG.KEVCADPKERWVRDsMKHLDQIFQNLKP
QPVGINTSTTC.CYRFINKKIPKQRLESYRRTTSSH.CPREAVIFKTKLD.KEICADPTQKWVQDFMKHLDKKTQTPKL
C Chemokine
LTN GVEVsDKRT CVS LTTQRLPVSR KTYT TEG. S LR. AVIF ITKRGLK VCADPQATWVRDVVRsMDRKsNTRNNMIQT
8FIG. 1. Multiple sequence alignment of human CXC, CC and C chemokines.
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bers of the CXC chemokine family3738 in parti-
cular PF-4, yIP-10 and MIG (monokine inducible
by gamma interferon). Recent investigations
have demonstrated that the three amino acids
preceding the first N-terminal cysteine (ELR) are
critical for the neutrophil chemotactic and
activating properties of these mediators.25 Most
of the ELR proteins are potent neutrophil
chemoattractants, and have the capacity to bind
a shared C-X-C chemokine receptor. In contrast,
proteins lacking the ELR motif, have an altered
chemotactic spectrum of activities and do not
seem to bind the shared CXC receptor. Thus, in
summary the chemokine superfamily may con-
sist of at least four different structurally and
functionally meaningful parts: (a) the CC sub-
family (); (b) the C subfamily (y); (c) the CXC
subfamily without ELR (non-ELR) ((z); (d) the
CXC subfamily with ELR (ELRCXC subfamily)
((z). A schematic representation is depicted in
Fig. 2.
The Chemokine Receptors
The molecular target for chemokines are their
cell surface receptors.36 The chemotactic signals
for leukocytes are transduced to heterotrimeric
G proteins by receptors with seven predicted
transmembrane domains. All of the chemokine
receptors have seven domains enriched in
hydrophobic amino acids, several of which are
conserved among most members of the G-
protein coupled receptor (GPCR) superfamily.
There are no specific amino acids or amino acid
patterns common to all chemoattractant recep-
tors which can distinguish them from other
types of GPCRs. Nevertheless, there are five
general properties, which makes the chemoat-
tractant receptors to a subfamily within the
GPCR superfamily: (1) their sequences are
similar in length, approximately 350 amino
acids, (2) they have over 20% amino acid
identity overall to each other, (3) the short third
intracellular loop is enriched in basic amino
acids. Many other GPCRs have long third intra-
cellular loops, (4) the N-terminal segments are
in most cases unusually acidic, and (5) their
RNAs are expressed in leukocytes.27
Signal transduction
The chemokine receptors are thought to regu-
late the activity of phospholipase C through
activation of the G-protein. The activated G-
protein causes a phospholipase C mediated
breakdown of phosphatidylinositol-4,5-bisphos-
phate (PIP2) to produce the second messengers
inositol-l,4,5-trisphosphate (1,4,5-IP3) and 1,2-
diacylglycerol (DAG). IP3 mobilizes intracellular
calcium, while DAG activates protein kinase C
(PRO.
Receptor Subtypes
Based on binding specificity and expression in
certain cell types, the chemokine receptors can
be classified in different ways. According to
ENA78 Eotaxin
mig IL-8 RANTES MCP-3
IP-10 SDF-la/lfi C10 C-C
MCP-2
PF-4 GCP-2 1309/ MCP-1
PBP MGSA/
gro a, fi, y
fi-TG NAP-2
CTAP-III
TCA3
Lymphotactin
MIP-lfi MIP-la
FIG. 2. Organization of the chemokine superfamily. Schematic depiction of a four-part superfamily structure, on the basis of
the arrangement of amino acids around the conserved cyststeines in the proteins. The name used for each of the
chemokines is that of the human protein, other names for homologues from other species may exist. The arrows originating
from PBP indicate that three proteins with distinct activities (-TG, CATP-III, and NAP-2) are proteolytically derived from that
molecule.39
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Schall and Bacon9 the receptors can, so far, be
grouped into four general classes.
Promiscuous receptors
The promiscuous receptor is a receptor that
binds chemokines of either CC or CXC classes.
To date, the only example of this receptor is the
erythrocyte chemokine receptor (ECKR). Hor-
uk, Chaudhuri, and co-workers have shown that
this erythrocyte chemokine binding protein is
identical to the Duffy blood-group antigen,
which is a receptor for the malarial parasite
Plasmodium vivax.4,41
Shared receptors
The shared receptor is a receptor which will
bind to more than one chemokine within either
the CXC or the CC class. Two examples are the
interleukin-8 receptor B (IL-8B receptor) and
the CC chemokine receptor-1 (CC CKR-1, also
called the MIP-lc/RANTES receptor). The IL-8B
receptor binds chemokines with the ELRCXC
motif (CXC class), whereas the CC CKR-1 binds
several of the CC chemokines.
Specific receptors
These receptors seem to bind only one specific
chemokine. The interleukin-8 receptor A (IL-8A
receptor) and the monocyte chemoattractant
protein (MCP)-I receptor represent this class.
Virally encoded receptors
To date there are two reports of virally encoded
receptors. One is encoded by a cytomegalovirus
open reading frame, CMV U28,42’43 and the
other from herpes saimiri virus, HS ECRF3.44
These two receptors are probably shared C-C
and C-X-C receptors respectively, that have been
transduced by viruses during evolutionay his-
tory.
Horuk24 uses another classification. The chemo-
kine receptors are divided into CXC chemokine
receptors, CC chemokine receptors, viral homo-
logues of chemokine receptors and the human
erythrocyte chemokine receptor. The CXC che-
mokine receptors contain the IL-8A and IL-8B
receptors. The CC chemokine receptors are
represented by (1) a MIP-I(x-MIP-1
-shared
receptor, (2) a MCP-l-specific receptor, and (3)
a MCP-1-MIP-I(-MIP-I[3-shared receptor. Shall
and Bacon39 refer to the MIP-l(z-MIP-l-shared
receptor as the MIP-I(z/RANTES receptor,
whereas the MCP-1-MIP-l(x-MIP-l-shared recep-
tor is not taken into account. The class of the
viral homologues of chemokine receptors and
the human erythrocyte receptors represent the
same receptors mentioned in the virally en-
coded receptors and promiscuous receptors by
Schall and Bacon respectively.
CXC Receptors
IL-8 is one of the best characterized CXC
chemokines and selective receptors for IL-8
were demonstrated by several binding studies
with human neutrophils. In general agreement
with other reports,43’46 Baggiolini and co-work-
ers47 found that human neutrophils possess on
average 64 500-t- 14 000/cell receptors with an
apparent Kd of 0.18 + 0.07 nM. Most of the
studies on IL-8 receptors were initially carried
out with [125I]IL-8, since IL-8 was the first CXC
chemokine that was available in sufficient quan-
tity for receptor characterization.24 Radiola-
belled IL-8 is displaced by cold IL-8, but also by
NAP-2 and GROcz. The displacement of IL-8 by
other CXC chemokines is bimodal, revealing the
existence of at least two types of receptors on
neutrophils, one with high affinity for all three
ligands (IL-SRB; Kd 0.1-0.3 nM), and the other
with high affinity for IL-8, but low affinity for
NAP-2 and GRO(z (IL-SRA; Ka 100-130 nM).45’46
Additionally, IL-8 is able to desensitize calcium
transients elicited by GRO(z and NAP-2, but
GROcz and NAP-2 do not desensitize the re-
sponse to IL-8.27 The existence of two IL-8
receptors is further supported by the cloning of
two cDNAs encoding seven-transmembrane-
domain receptors, and causing binding
4
of CXC
7chemokines to cells upon transfection. These
products have been referred to as IL-8 receptors
A and B, B and A, (z and [3 and Type 1 and Type
2 in literature, but in this review they will be
termed A and B following the gene symbols
published by Murphy.27 The deduced sequences
of the IL-8A receptor and the IL-8B receptor are
highly homologous at the amino acid level
(77%), whereas they are 23-30% homologous
to other leukocyte chemoattractant receptors
(Fig. 3).27 IL-8A and IL-SB receptors have the
highest homology over the membrane-spanning
regions, and diverge at the amino and carboxyl
termini.48
The IL-8RA (specific receptor which binds
only IL-8) is more widely expressed than the IL-
8RB (shared receptor) and is found on neutro-
phils as well as at low levels on monocytes and
monocytic cell lines, melanoma cell lines, T
cells, synovial fibroblasts, HL-60 and THP-1
myeloid precursor cell lines.24’47 The expression
of the IL-8RB receptor is more restricted and
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IL-8R-A
IL-8R-B
CC-CKR-1
CC-CKR-2
CC-CKR-3
CC-CKR-4
IL-8RA
IL-8RB
CC-CKR-1
CC-CKR-2
CC-CKR-3
CC-CKR-4
IL-8RA
IL-8RB
CC-CKR-1
CC-CKR-2
CC-CKR-3
CC-CKR-4
IL-8RA
IL-8RB
CC-CKR-1
CC-CKR-2
CC-CKR-3
CC-CKR-4
IL-8RA
IL-8RB
CC-CKR-1
CC-CKR-2
CC-CKR-3
CC-CKR-4
IL-8RA
IL-8RB
CC-CKR-1
CC-CKR-2
CC-CKR-3
CC-CKR-4
MESDSFEDFW KGEDLSNYSY SSTLPPFLLD AAPCEPESLE INKYFVVIIY
MSNITDPQMW DFDDLN FTGMPPADED YSPCMLETET LNKYVVIIAY
METP NTTE. DYD TTTEFDYGDA TPCQKVNERA FGAQLLPPLY
MLSTSRSRF IRNTNESGEE VTTFFDYDYG APCHKFDVKQ IGAQLLPPLY
MTTS LDTVE. TFG TTSYYD. DVG LLCEKADTRA LMAQFVPPLY
MNPTDI ADTTLDESIY SNYYLYESIP KPCTKEGIKA FGELFLPPLY
51
ALVFLLSLLG NSLVMLVILY SRVGRSVTDV YLLNLALADL LFALTLPIWA
ALVFLLSLLG NSLVMLVILY SRVGRSVTDV YLLNLALADL LFALTLPIWA
SLVFVIGLVG NILVVLVLVQ YKRLKNMTSI YLLNLAISDL LFLFTLPFWI
SLVFIFGFVG NMLVVLILIN CKKLKCLTDI YLLNLAISDL LFLITLPIWA
SLVFTVGLLG NVVVVMILIK YRRLRIMTNI YLLNLAISDL LFLVTLPFWI
SLVFVFGLLG NSVVVLVLFK YKRLRSMTDV YLLNLAISDL LFVFSLPRWG
TM 1 > < TM2
101
A.SKVNGWIF GTFLCKVVSL LKEVNFYSGI LLLACISVDR YLAIVHATRT
A.SKVNGWIF GTFLCKVVSL LKEVNFYSGI LLLACISVDR YLAIVHATRT
DYKLKDDWVF GDAMCKILSG FYYTGLYSEI FFIILLTIDR YLAIVHAVFA
H SAANEWVF GNAMCKLFTG LYHIGYFGGI FFIILLTIDR YLAIVHAVFA
HYVRGHNWVF GHGMCNLLSG FYHTGLYSEI FFIILLTIDR YLAIVHAVFA
YY.AADQWVF GLGLCKMISW MYLVGFYSGI FFVMLMSIDR YLAIVHAVFS
> < TM 3 >
151
LTQKRY.LVK FICLSIWGLS LLLALPVLLF
LTQKRH.LVK FVCLGCWGLS MNLSLPFFLF
LRARTVTFGV ITSIIIWALA ILASMPGLYF
LKARTVTFGV VTSVITWLVA VFASVPGIIF
LRARTVTFGV ITSIVTWGLA VLAALPEFIF
LRARTLTYGV ITSLATWSVA VFASLPGFLF
< TM 4 >
201
TANWRMLLRI LPQSFGFIVP
TAKWRMVLRI LPHTFGFIVP
LREWKLFQAL KLNLFGLVLP
.RGWNNFHTI MRNILGLVLP
VYSWRHFHTL RMTIFCLVLP
T.TWKVLSSL EINILGLVIP
TM 5
RRTVYSSNVS PACYEDMGNN
TQAYHPNNSS PVCYEVLGND
SKTQWEFTHH TCSLHFPHES
TKCQKEDSVY VCGPYFP...
YETEELFEET LCSALYPEDT
STCYTERNHT YCKTKYSLNS
LLIMLFCYGF TLRTLFKAHM GQK.HRAMRV
EFVMLFCYGF TLRTLFKAHM GQK.HRAMRV
LLVMIICYTG IIKILLRRPN EKK.SKAVRL
LLIMVICYSG ILKTLLRCRN EKKRHRAVRV
LLVMAICYTG IIKTLLRCPS KKK.YKAIRL
LGIMLFCYSM IIRTLQHCKN EKK.NKAVKM
> <
251
IFAVVLIFLL CWLPYNLVLL ADTLMRTQVI QETCERRNHI DRALDATEIL
IFAVVLIFLL CWLPYNLVLL ADTLMRTQVI QETCERRNNI GRALDATEIL
IFVIMIIFFL FWTPYNLTIL ISVFQDFLFT HE.CEQSRHL DLAVQVTEVI
IFTIMIVYFL FWTPYNIVIL LNTFQEFFGL SN.CESTSQL DQATQVTETL
IFVIMAVFFI FWTPYNVAIL LSSYQSILFG ND.CERSKHL DLVMLVTEVI
IFAVVVLFLG FWTPYNIVLF LETLVELEVL QD.CTFERYL DYAIQATETL
TM 6 >
301
IL-8RA GILHSCLNPL
IL-8RB GFLHSCLNPI
CC-CKR-1 AYTHCCVNPV
CC-CKR-2 GMTHCC ImP I
CC-CKR-3 AYSHCCMNPV
CC-CKR-4 AFVHCCLNP I
TM 7
IYAFIGQKFR HGLLKILAIH GLISKDSLPK
IYAFIGQNFR HGFLKILAMH GLVSKEFLAR
IYAFVGERFR KYLRQLFHR. RVAVHLVKWL PFLSVDRLER
IYAFVGEKFR RYLSVFFRK. HITKRFCKQC PVFYRETVDG
IYAFVGERFR KYLRHFFHR. HLLMHLGRYI PFLPSEKLER
IYFFLGEKFR KYILQLFKTC RGLGVLCQYC GLLQIYSADT
351
IL-8RA DSRPSFVGSS SGHTsTTL
IL-8RB HRVTSY.TSS SVNVSSNL
CC-CKR-I VSST.SPSTG EHELSIVF
CC-CKR-2 VTSTNTPSTG EQEVsAGL
CC-CKR-3 TSSV.SPSTA EPELSIVF
CC-CKR-4 PSSSYTQSTM DHDLHDAL
FIG. 3. Multiple protein sequence68alignment of the human chemokine receptors. The seven putative transmembrane
sequences are indicated by arrows.
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confined primarily to myeloid cells including
neutrophils, HL-60, THP-1 and AML 193
cells.24,27 This suggests that the reported ability
of IL-8 to attract small numbers of T cells may
be mediated by IL-SRA.27
Regulation of the expression of the
IL-8 receptor A/B
It has been reported that [125I]IL-8 bound to the
IL-SR on neutrophils is rapidly internalized and
degraded in lysosomes.49-51 More than 90% of
the ligand-bound receptors are endocytosed
within 10 min at 37C, and the receptors are
recycled, as indicated by their re-expression on
the cell surface approximately 10 min later.49
Inhibitory lysosomotropic agents (agents that
show a special affinity for lysosomes), including
ammonium chloride, inhibit the internalization
process. Ammonium chloride also inhibits che-
motaxis, suggesting that chemotaxis may re-
quire internalization and reexpression of the IL-
528 receptor. Chuntharapai and Kim investigated
the rate of down-modulation of IL-SRA/B ex-
pression by IL-8 on neutrophils and found that
regardless of the expression level of IL-8RA and
IL-SRB among different blood donors,53 the ECs0
of IL-8 required for the down-modulation of IL-
8RA was higher than that of IL-SRB. It was
found to be impossible to down-modulate IL-
8RA/B completely and this is probably due to
the two ongoing competitive processes: .down-
modulation of receptors by. the agonist and
reappearance of receptors after dissociation
from the bound ligand.
Investigations concerning the recycling of the
receptors revealed that after the exogenous IL-8
was removed, the level of IL-SRA continued to
increase and reached 85% of the untreated fresh
control level during a 1.5-h culture period. In
contrast, the level of IL-SRB recovered to only
40% of the control value during a 1-h culture
period and then remained at that level. The
rapid re-expression of IL-SRA, with respect to
IL-SRB, after ’complete’ down-modulation sup-
ports the hypothesis that IL-8RA may play a
more active role in transmitting the IL-8 signal
in the inflammatory area compared with IL-
8RB.52
It has been generally accepted that IL-8RA/B
have similarly high affinities for IL-8,225455
although the magnitudes of the affinities re-
ported varied from 0.1 to 4 nM. It is striking,
that Chuntharapai and I{im52 have a different
view, by stating that their results obtained from
the comparison of the EC50 of IL-8 and the K
of each receptor for IL-8 clearly demonstrate
that IL-8RB has a higher affinity for IL-8 com-
pared with IL-8RA. They detected seven- to 13-
fold and two- to five-fold differences in the EC50
of IL-8 and the Kd values, respectively.
As a result, they proposed a mechanism that
could occur during inflammation. In the course
of inflammation, resident macrophages and
fibroblasts, located at the site of inflammation,
secrete IL-8, and this secreted IL-8 gradually
reaches nearby blood vessels. At a distant site,
the concentration of IL-8 could be in the
picomolar range, and at these concentrations IL-
8RB would receive the IL-8 signal first and
initiate the migration of neutrophils toward the
inflammatory area. As neutrophils migrate clo-
ser to the site of inflammation, the IL-8 concen-
tration can increase to the nanomolar range. At
these IL-8 concentrations, IL-8RA would be the
major receptor involved in mediating the IL-8
signal, since few IL-8RB would remain on the
cell membrane.52 Thus, the different affinities of
IL-8RA/B for IL-8 may result in a different
function; the low affinity IL-8RA may play an
active role in mediating IL-8 signal in the
inflammatory area, while the high affinity IL-
8RB may initiate the neutrophil migration in a
distant area of infection.
Amino acids important for ligand
binding: location of the active site
IL-8 may be an important mediator in various
inflammatory exudates, including synovial fluid
from patients with rheumatoid arthritis56 and
sputum from patients with cystic fibrosis,
chronic bronchitis, or bronchiectasis.7 Small
molecule antagonists of IL-8 may therefore have
the potential to be powerful anti-inflammatory
agents. In order to assist the rational design of
such compounds, it is important to elucidate
the structure/function relationships of IL-8 and
its receptors.
It has been reported that the N-terminal
region of IL-8 is critical for ligand binding to
neutrophils.5758 In particular, the single point
substitution of Arg6 by Ala or Lys causes a 1000-
fold decrease in the affinity of the ligand for its
receptor.58 Mutation of other amino acids in this
region do not lead to a similar decrease in
binding affinity. As the guanidinium side chain
of the Arg6 residue of IL-8 is positively charged
and is known to be pointing away from the
core of the molecule,58 it is likely to be poised
to directly interact with a negatively charged
amino acid side chain exposed on the ligand-
accessible surface of the IL-8 receptor. By site-
directed mutagenesis with systematic substitu-
tion of all the acidic residues present on the
surface of the type A IL-8 receptor, this key
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residue was identified.56 In the GPCR family, the
ligand accessible surface is defined as the
combination of the extracellular domain and
part of the transmembrane domain. It is inter-
esting to note that Asp85, which is located in
the second transmembrane domain of the re-
ceptor (Fig. 4), is conserved in more than 90%
of the members of the GPCR superfamily and
may be a key residue maintaining the tertiary
structure and proper folding of the receptor.
Replacement of Glu275 or Arg280 from the
receptor by Ala causes a complete loss of IL-8
receptor binding. Sequence alignment shows
that these residues are strictly conserved in the
two human (type A and B), the rabbit, and the
mouse IL-8 receptors. This demonstrates that
the third extracellular loop of the receptor,
which includes these Glu275 and Arg280, is an
important functional domain of the receptor.
Although Glu275 appears to be critical for
binding, there is no evidence that it is involved
in a direct interaction with the Arg6 of IL-8.
Hbert and co-workers56 speculate that Glu275
and Arg280 interact with Arg6 and Glu4 of IL-8,
respectively.
The presence of Aspll in the receptor
appears to be critical for IL-8 binding as well,
but it can be substituted with another acidic
residue, such as Glu, or with Lys (found at the
equivalent position in the IL-8RB). The substitu-
tion with Lys suggests that either Lysl 1 recruits
a new and favourable interaction with IL-8
(analogous to that of IL-SRB with IL-8) or that
the cavity created by mutating Asp l 1 to Ala is
particularly disadvantageous. Results of studies
with chimeric receptors in which the N-term-
inal segments of IL-8RB and rablL-8R or IL-8RB
and IL-8RA are switched clearly implicate this
domain in determining the selectivity of the
receptors.27’48 Moreover, because cz chemokines,
such as IL-8, are fairly basic proteins (pI of ILS:
8-8.5),56 the highly acidic N-termini of the IL-
8RA/B could be a major determinant for ligand
binding.
Nearly all members of the GPCR superfamily
have a pair of conserved cysteines in extracel-
lular loops 1 and 2, which are thought to form a
disulphide bridge linking these two loopss9 (Fig.
4). Human IL-8 receptor type A and B as well as
rabbit and mouse IL-8 receptor each contain
two additional cysteines: one in the N-terminal
region and the other in the extracellular loop 3
NH2
Asp 11 Cys30 S, Cys 277
Cys 277 S Cys 30 Glu 275
Arg 280
99
-S-
175 203 265 291
68 75 154 227’ 241 313
Asp 85
FIG. 4. Model for the secondary structure of IL-8 receptor type A. Residues that are critical for ligand binding are indicated in
black. Asp 85 is conserved in more than 90% of the members of the GPCR superfamily and may be a key residue maintaining
the tertiary structure and proper folding of the receptor.
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(in the case of IL-8RA: Cys30 and Cys277). the receptor, however, are lower than for
These two cysteines are very likely to interact RANTES, which indicates that the third promis-
with each other, forming a disulphide bridge cuous receptor mentioned was perhaps the
which brings the N-terminal region and extra- primary RANTES receptor, even though this
cellular loop3 of the receptor in close spatial receptor could accommodate also the other
proximity. H6bert et aL56 propose that Asp l 1, ligands.8 This promiscuous receptor was called
Glu275, and Arg280 of the IL-8 receptor type A the MIP-lc receptor,24 the MIP-lc/RANTES
are brought in close spatial proximity to each receptor or the CC CKR1, the high affinity for
other by a disulphide bridge between Cys30 RANTES has however not been found in the
and Cys277 and constitute a major binding study of Neote et aL42
domain for IL-8. The binding domain of the IL- In 1993 only one gene had been reported for
8RB receptor will be defined in a similar way. a leukocyte CC chemokine receptor, the human
MIP-I/RANTES receptor.27 The receptor be-
CC Chemokine Receptors longs to the GPCR superfamily, and its amino
acid sequence showed approximately 32% iden-
Over the past few years several new findings tity with the IL-SA and IL-SB receptors, but only
were published, which have significantly ex- approximately 23% identity with the C5a and
tended the knowledge about CC chemokine fMet-Leu-Phe (classical chemoattractant)recep-
receptors. In 1993, direct binding data for the tors. Thus MIP-Iz, MIP-I, MCP-1 and RANTES
CC chemokines were sparse compared with all bind to the CC CKR1 with varying affinities
that for the CXC chemokine receptors. A and all four ligands can cross-compete for
limited number of studies using radiolabelled binding.24 Chemokine binding affinity does not
MIP-Iz and MIP-I have been described. Inter- predict how well the ligand will transmit a
estingly these radiolabelled chemokines could signal through the receptor: RANTES and MIP-
be displaced by the CC chemokines MCP-1 and lz induce a similar intracellular calcium flux (at
RANTES, but not by the CXC chemokines IL-8 concentrations of 10-100 nM) while binding
and MIP-2. All four of these CC chemokines with disparate affinities, whereas MCP-1 and
(MIP-Iz/B, MCP-1, and RANTES) stimulated MIP-I induce calcium mobilization only at high
monocytes to carry out a variety of functions, concentrations (20% of the RANTES/MIP-Iz
and MIP-Iz, MIP-I, and RANTES had also been response at 1 M).
shown to stimulate chemotaxis and adhesion of Since 1993 new information became available
T cells.8 In addition, the members of this group concerning these receptors and in 1995 cDNAs
attracted and activated polymorphonuclear leu- for four human leukocyte CC chemokine recep-
kocytes (PMN), eosinophils and lymphocytes tots have been cloned. These receptors are
with variable selectivity and MIP-I had been designated CC CKR1, CC CKR2A and CC
shown to regulate the proliferative capacity of CKR2B (a single gene that produces two splice
myeloid progenitor cells6 variants that differ in their carboxy terminal
Competitive inhibition studies using various domains,63 also known as MCP-1 receptors A
CC chemokine ligands demonstrated that these and B) and CC CKR3. The properties of the first
chemokines and their receptors exhibited pro- three receptors are not fully consistent with
miscuity similar to that of the CXC chemokine eosinophil chemotactic responses to CC
subfamily and the IL-8 receptors. MCP-1 binding chemokines.64 MIP-I and RANTES are efffec-
could be partially displaced by either MIP-Iz or tive agonists for CC CKR1; however, its RNA is
MIP-I. MIP-Iz binding could be completely scarce in eosinophils. Much higher expression
displaced by MIP-I, and vice versa, and both is found in neutrophils, monocytes and lym-
were partially (30%) displaced by MCP-1.61 phocytes.6 MCP-1 is an agonist for CC CKR2A
These results suggested that at least three types and -2B, but it does not activate eosinophils.
of CC receptors were expressed on monocytic Moreover, CC CKR2 RNA is expressed in mono-
65cells: (1) a specific receptor for MCP-1, (2) a cytes but not in eosinophils. CC CKR3 is the
shared receptor for MIP-Iz and MIP-I, which first eosinophil-selective member of this family.
binds both ligands with equal affinity, and (3) a The CC CKR3 cDNA is 1.6 kb in length and it
shared receptor for MIP-Iz, MIP-I and MCP-1. encodes a predicted protein of 355 amino acids
Additional studies with [125I]RANTES indicated that is identical in length and 63% identical in
that RANTES bound with an affinity of 400- sequence with CC CKR1. CC CKR3 has 51%
600 pM to monocytes and expressed approxi- identity with CC CKR2B but only 31% identity
mately 600 receptors per cell.62 RANTES bind- with the CXC chemokine receptor and IL-8
ing could be completely displaced by MCP-1, receptors A and B (Fig. 3). The amino acid
MIP-Iz and . The affinities of these ligands for positions that differ between CC CKR1 and CC
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CKR3 are found mostly in the (putative) extra-
cellular domains and adjacent portions of the
transmembrane domains. Like CC CKR1 and all
other known chemokine receptors, the CC
CKR3 sequence is acidic in the N-terminal
segment before the first putative transmem-
brane domain. The second extracellular loop is
also highly acidic, whereas for CC CKR1 the
corresponding region is basic. In agreement
with all other known chemokine receptors, CC
CKR3 has conserved cysteine residues in the N-
terminal segment and the third predicted extra-
cellular loop that could form a disulphide
bond.64
Distribution of CC CKR3 RNA
The mRNA encoding the CC CKR3 receptor
was first established in human peripheral blood-
derived eosinophils and in small amounts in
neutrophil and monocyte samples. Combadiere
et aL64 however, detected CC CKR1 mRNA in
large amounts in neutrophil and monocyte
samples and trace amounts in eosinophils.
mRNA for CC CKR2B was found only in mono-
cyte samples. Thus, CC CKR1,-2 and-3 are
differently expressed in a cell type-specific
pattern in human peripheral blood leukocytes.
Since MIP-Iz, RANTES, and MCP-3 are the
only known human CC chemokines that acti-
vate eosinophils, they were the best candidate
agonists for CC CKR3. However, when three
independent human embryonic kidney (HEK)
293 cell clones stably transfected with CC
CKR3 were tested, all three exhibited [Ca2+]
transients in response to MIP-Iz, RANTES, and
MIP-I but not in response to MCP-1, MCP-2,
MCP-3, IL-8 or ,IP-IO. The rank order of
potency was MIP-lc > RANTES > MIP-I. As
previously reported, HEK 293 cells stably trans-
fected with CC CKR1 also responded to MIP-lc
and RANTES.42 However, unlike CC CKR3, CC
CKR1 transfected cells also responded to MCP-3
but not to MIP-I at lOOnM. Since MIP-I,
RANTES, and MIP-I are agonists for CC CKR3,
they must bind to it. Nevertheless, Combadiere
64and colleagues have not yet been able to
demonstrate specific binding of [125I]MIP-lz
and [125I]RANTES to CC CKR3-transfected HEK
293 cell using as much as 0.5 nM radioligand on
2 million transfected cells. This suggests that
MIP-lc, MIP-I and RANTES activate CC CKR3
via low binding interactions. In 1995 it was
reported that it may well be that CC CKR3 is
more selective for another, as yet untested, CC
66
chemokine such as eotaxin. Human eotaxin
was not yet identified at that time. In January
1996, it was reported that this receptor indeed
functions in response to eotaxin.67 The studies
strongly suggest that normal human monocytes
and eosinophils respond to MIP-1 cz and RANTES
via two MIP-lc/RANTES receptors, CC CKR1
and CC CKR3. The relative RNA distributions
suggest that CC CKR1 functions principally, but
not exclusively, in monocytes, and CC CKR3
functions principally, but not exclusively, in
eosinophils.
Only very recently, Wells et al.6 reported the
identification of a fourth CC chemokine recep-
tor in the human basophilic cell line KU-812.
They have called it K5.5, or CC CKR4 and this
receptor shows 49% identity with CC CKR1
over 356 amino acids, 46% identity to the CC
CKR2 (form B) over 360 amino acids, and 45%
with CC CKR3 over 356 amino acids. Northern
blot analysis showed high levels of expression
of CC CKR4 in the thymus and in peripheral
blood leukocytes. They also showed that CC
CKR4 was specifically expressed in T-cells, B-
cells, and monocytes, as well as in platelets.
Human basophils showed barely detectable CC
CKR4 expression. However, after stimulation
for 15 min with IL-5 (lOng/ml) there was a
significant up-regulation of receptor mRNA ex-
pression. The ligands for CC CKR4 were initially
determined to be MCP-1, MIP-lc, and RANTES
from measurements of Ca2+-activated chloride
currents in Xenopus laevis oocytes injected
with cRNA for CC CKR4. The results for MIP-I
and RANTES have been confirmed by .binding
experiments using transfected cell lines.68
The Erythrocyte Receptor
Erythrocytes have long been appreciated as
transporters and exchangers of 02 and CO2
between the lungs and tissues. The observation
that IL-8 can bind to erythrocytes in a saturable
manner, suggested a role for erythrocytes as
potential mediators of inflammatory processes.
In contrast to the cloned receptors described, a
promiscuous receptor on red blood cells has
been characterized, that binds a wide variety of
inflammatory peptides of both the CXC and CC
groups within the chemokine superfamily.41’69
The human erythrocyte chemokine receptor,
which was originally postulated to be a ’sink’
for IL-87 binds the CXC chemokines IL-8, MGSA
and PF-4, and the CC chemokines MCP-1 and
RANTES with equal high affinity.24 Other experi-
ments show that the RBC-bound IL-8 (and most
likely other chemokines) does not induce signal-
ling in target cells and that chemokines bound
to the red cell surface are inaccessible to their
normal target inflammatory cells.69 Thus, the
major role for the red cell chemokine receptor
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may be one of a clearance receptor for chemo- and thus the thermodynamics will strongly
tactic and inflammatory peptides in the blood, favour dimerization.6 Third, IL-8, which con-
Due to the broad ligand specificity of the red tains N-methyl-leucine 25, is always monomeric
blood cell receptor, it has been designated the and yet remains active.72
multispecific chemokine (CK) receptor.1
The fact that the molecular mass of the
erythrocyte CK receptor is at least 19 kDa Structure-Activity of CXC
smaller than the molecular mass of the cloned Chemokines
IL-8 receptors, as well as the ability of the CK The ELR motif
receptor to bind to a variety of chemokines,
supports the idea that this receptor has a As already mentioned in the introduction of this
different structure compared to the cloned IL-8 section the ELR motif is the most critical region
receptors. Moreover, the CK receptor showed for interaction with the IL-SR.36 Mutagenesis
no sensitivity to GTP or to GTPyS at concentra- and peptide synthesis showed that out of all of
tions which resulted in a 50% reduction in IL-8 the charged residues, in IL-8 only the amino-
binding to plasma membranes prepared from terminal Glu4-Leu5-Arg6 (ELR) sequence was
cells transfected with one of the cloned IL-8 absolutely required. The ELR region can be
receptors.7 These data do not support the idea modified such that the receptor binding is
that the CK receptor is G-protein linked. It is retained but activity is lost. It is striking that
still possible, however, that the erythrocyte CK these antagonists have much lower receptor
receptor retains the seven transmembrane do- affinity than IL-8, because usually antagonists
main characteristic of this family of receptors, have higher binding affinity than agonists.
but that it is uncoupled from its guanine Therefore, this indicates that the ELR motif is
nucleotide transducing unit. Alternatively, the both a binding and receptor-activation motif.73
erythrocyte CK receptor may have a unique Multiple substitutions showed that all three
three-dimensional protein structure compared residues of the ELR motif were highly sensitive
with that of the cloned IL-8 receptors. Evidence to modification, with the order of sensitivity
in support of either of these two possibilities being R >> E > L.3 Additionally, the ELR confor-
awaits purification and sequencing of this mation and side chain integrity is critical, as
protein.4 substitution of NMe-Leu and NMe-Arg, or single
D-amino acid substitutions greatly reduced activ-
Structure-Activity Relationships ity. Adding ’spacer’ residues, either Glu or Ala,
of Chemokines between the ELR and the cysteine at position 7
resulted in loss of activity with only some
The compact, symmetrical nature of the familiar residual binding. ELR effects are subtly context-
IL-8 dimer structure led to the widespread dependent since PF-4, but not ,IP-IO or MCP-1,
presumption that the dimer form must be binds to IL-8 receptors and activates neutrophils
important for function. This notion is extended when its N-terminus is modified to contain
further by the finding that MIP-I has an ELR74
entirely different mode of dimerization. Thus it ELR-containing N-terminal peptides of IL-8
has been suggested that all the CXC chemo- lack agonist activity, indicating that ELR may be
kines have a six-stranded
-sheet dimer (three necessary but not sufficient for receptor activa-
antiparallel
-strands from each monomer), tion. The helical C-terminal domain of IL-8
whereas all the CC chemokines an end-on-end also contains determinants for receptor acti-
dimer structure and, moreover, that this struc- vation.27
tural difference may account for the functional
differences between the two families. Lusti-
Narasimhan et al.72 and Clark-Lewis et aL36 The loop region
present the case from an opposite viewpoint: The loop region, consisting of amino acids 10-
that the functional form is the monomer and 22, was generally not affected by single substi-
dimerization is not relevant for interaction with tutions. However, experiments with hybrid
the functional receptor. There are several rea- proteins of IL-8 and yIP-10 demonstrated that
sons for this hypothesis. First, ligands for the this entire region was critical for IL-8 activity.
GPCRs are mostly small peptides or nonpeptide The residues close to the NH2-terminal end of
hormones and mediators. Therefore, it seems the loon i.e. close to cysteine 9, were the most
unlikely that the chemokine receptors accom- critical. The major difference between the
modate chemokine dimers. Second, protein single substitution and hybrid strategies is that
structures are determined at high concentration the hybrids had multiple replacements. Thus,
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only when several substitutions were made, MCP-1, addition of a residue to the NH2-terminal
significant effects were observed. Taken to- or acetylation of the NH2-terminal glutamine
gether, the results suggest that the N-terminal resulted in loss of activity. Analogues with the
loop comprises a secondary binding site.27 The NH2-terminal residue converted to Asn, or
amino acids 18-22, however, do not appear to residues with nonpolar side chains of varying
be essential, as multiple substitutions in this size, had equivalent activity to native MCP-1.
region failed to affect activity. Phe21 makes Analogues that had either one, two or three
aromatic contacts with Tyrl 3, Phel7, and residues deleted from the NH2-terminal had
Trp57 and may have a structural role. Never- lower binding affinity and activity than full-
theless, the possibility that Phe21 has hydro- length native MCP-1. However, MCP-1, 5-76
phobic or aromatic contacts with the receptor had surprisingly significant activity and bound
cannot be ruled out.6 to the MCP-1 receptor.6 Further deletions
resulted in analogues that had significant bind-
The disulphides ing to the receptor but no functional activity.Clark-Lewis and co-workers36 propose the ex-
When the cysteines that form each disulphide istence of an activation region and a receptor
bridge were substituted in pairs with the binding region that comprise residues 1-5 and
cysteine isostere, a-aminobutyric acid (side 7-10 respectively. Truncation of the NH2-term-
chain CH2-CH3) both analogues were inactive inal region (up to the first cysteine) of MCP-1
and NMR studies showed significant structural resulted in MCP-1, 11-76, which had residual
perturbation, probably due to loss of the binding activity, suggesting that a second region
disulphide. Both disulphides are essential for binds, although with low affinity, independently
function, indicated by lack of activity of the two of residues 1-10.75 This contrasts with the CXC
analogues. However, they do not seem to be chemokines, where truncation of the ELR motif
essential for chemokine function in general, as resulted in absence of receptor binding. Experi-
lymphotactin, which lacks both disulphide ments with hybrids of MCP-1 and MCP-3 led to
bridges, is still a chemoattractant.27 the suggestion that the NH2-terminal is not
sufficient to determine activity, and that the
NH2-terminal binding site and secondary sitesThe 30-35 region
complement each other to give maximal bind-
His33 was analysed extensively due to its inter- ing and activity. The CC chemokines were
action with the CXC region and proximity to analysed for the chemotactic activity on mono-
the two disulphides and the ELR motif, but cytes and THP-1 cells. The order of potency
various substitutions had no effect on activity, was MCP-1, MCP-3, MCP-2, RANTES, MIP-I
Further analogues showed that the Gly31- and MIP-I. It was found that MCP-3 and MCP-2
Pro32 motif in the 30-35 region was essential, both stimulate chemotaxis, enzyme release, and
This motif determines the structure of the 30- intracellular calcium induction in monocytes
35 region, and, most likely, also the 7-34 and THP-1 cells and enzyme release in mono-
disulphide. The 7-34 disulphide would in turn cytes. MCP-3 is always the more potent of the
influence the conformation of the ELR motif, two. MCP-3 and MCP-2 appear to be function-
Structure-Activity of the CC
Chemokines
Based on the sequence homology of chemo-
6kines, Clark-Lewis and co-workers3 hypothe-
sized that there could be similarities in the way
ally similar and both stimulate basophils, eosino-
phils, and lymphocytes, as well as monocytes.
This is in contrast to published findings suggest-
ing a distinct mechanism of action for MCP-2.36
Mutation of Leu25 and Va127 in IL-8
that CXC and CC chemokines interact with Examination of the sequences of the CXC
their receptors. They speculated that the N- chemokines reveals that the highly conserved
terminal region would be critical and that leucine, corresponding to Leu25 in IL-8, is in all
secondary sites would be necessary. However, cases replaced by a tyrosine in CC chemokines.
instead of just three residues as in the CXC There is also a high degree of conservation
chemokines, the entire 10 residues that are among the CXC chemokines of the adjacent
NH2-terminal to the first cysteines were impor- Va127 residue, which protrudes from the same
tant. Deletion of the first residue of MCP-1 side of the
-sheet as Leu25. In RANTES, Va127
markedly decreased activity. This contrasts with is also replaced by a tyrosine. Mutation of either
the CXC chemokines, where only the ELRCXC Leu25 or Va127 to tyrosine residues results in a
motif of the N-terminal region is essential. For decrease in affinity for the IL-8 receptor on
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neutrophils and a simultaneous decrease in the
physiological response of neutrophils. The mu-
tation Leu25 > Tyr has the more dramatic
effect, showing a 100-fold drop in receptor
binding. This mutation in IL-8 induces a novel
monocyte chemotaxis activity, indicating that
Leu25 and Va127 are important in the inter-
action not only with the neutrophil IL-8 recep-
tors, but also with the monocyte CC chemokine
receptors72 Previous studies have already
shown that substitution of Tyr28 and Arg30 in
the first
-sheet of MCP-1 with the correspond-
ing residues found in IL-8 resulted in a switch
from monocyte to neutrophil specificity for the
mutated molecule.76
Transendothelial Migration of
Leukocytes
Recruitment of leukocytes to sites of localized
inflammation is a feature of several human
disease states. There is a diverse range of
leukocyte types and functions, and the different
cells appear to migrate to the appropriate site
in an impressively ordered and regulated man-
ner. It is this highly elaborate process of cell
influx that is the hallmark of the inflammatory
process77 The histology of inflamed sites can
differ markedly. The acute infiltrate in common
bacterial infections, or after local deposition of
IgG immune complexes is mainly neutrophil,
whereas mononuclear cells predominate in
infections by intracellular pathogens, and in
delayed-type hypersensitivity. By contrast, eosi-
nophil and basophil leukocytes are prominent
in inflammatory reactions that follow immedi-
ate-type allergy, certain parasitic infections and
autoimmune events.78 Moreover, increased num-
bers of eosinophils have been reported in the
lung tissues and airways of patients affected by
a number of respiratory pathologies including
nasal polyposis and asthma.39
The in vivo requirements for a trafficking cell
are quite complicated, and broadly include four
distinct components: circulation, adhesion, dia-
pedesis (migration through junctions between
endothelial cells), and migration.9 Until re-
cently, the mechanisms for the recruitment of a
given type of leukocyte into inflamed tissue
remained largely a mystery, since most inflam-
matory cytokines, mediators and chemoattrac-
tants have little target cell selectivity. It was
suggested that some selectivity may result from
the type of adhesion receptors expressed on
endothelial cells, e.g. vascular cell adhesion
molecule (VCAM) recognition of very late anti-
gen 4 (VLA-4), which is present on monocytes,
basophils and eosinophils, but not neutrophils.
Furthermore, priming by haematopoietic growth
factors can also influence the type of cellular
infiltrate. For instance, IL-3 and IL-5 markedly
enhance the migration and release responses of
eosinophil and basophil leukocytes, but do not
affect neutrophils.78
In the past few years, an improved under-
standing of cell adhesion and intracellular sig-
nalling have helped to unravel some of the
details of this important, but complex,
process.77 First, leukocytes must overcome hae-
modynamic forces in order to adhere to the
endothelial cell surface, lining the typical vessel
wall. Subsequently, they must ’crawl their way’
along the endothelial surface, migrate through
junctions between endothelial cells (the process
of diapedesis), and penetrate the basement
membrane before gaining entry into, and migra-
tion through, the tissue spaces.9 The inflamma-
tory process is now thought to be a multi-step
phenomenon with contributions from four dif-
ferent families of adhesion molecules, including
the selectins and their related carbohydrate and
glycoprotein ligands, the integrins and their
related immunoglobulin superfamily ligands,
and a diverse set of small signalling molecules
known as chemokines and their respective
receptors.77 The coordinated expression of ad-
hesion receptors on the surface of the leuko-
cytes and their counterreceptors on the surface
of endothelial cells are thought to be a key link
in the process. Models of the adhesion compo-
nent of leukocyte trafficking have been refined
into a ’three step’ process comprising: (a)
rolling of leukocytes along the vasculature
(mediated through transient interactions be-
tween so-called selectin proteins and their
carbohydrate ligands), followed by (b) activa-
tion of the cell (induced by classical chemo-
attractants or chemokines) resulting in firm
adhesion (mediated through integrin molecules)
leading ultimately to (c) extravasation (crawling
along the endothelium, diapedesis, and migra-
tion into tissues), presumably in response to a
chemoattractant gradient.9 A key feature is that
selectin-carbohydrate, chemoattractant-recep-
tor, and integrin-immunoglobulin family inter-
actions act in sequence, not in parallel. This
concept has been confirmed by the observation
that inhibition of any one of these steps, with
e.g. selectin antagonists, gives essentially com-
plete rather than partial, inhibition of neutro-
phil and monocyte migration.79 An important
consequence of a sequence of steps, at any one
of which are choices of multiple receptors or
ligands that have distinct distributions on leuko-
cyte subpopulations or endotheliurn, is that it
provides great combinatorial diversity for regu-
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lating the selectivity of leukocyte localization in lipopolysaccharide or TNF and requires de novo
vivo, as has been emphasized in several re- mRNA and protein synthesis. Selectins mediate
views.8-2 Each type of leukocyte responds to a function unique to the vasculature, the attach-
a particular set of area code signals. Inflamma- ment or tethering of flowing leukocytes to the
tion alters the expression and location of the vessel wall through labile adhesions that permit
signals on vascular endothelium. Chemoattrac- leukocytes to roll in the direction of the flow.
tants provide the greatest number of molecular
choices and thus the greatest cellular speci- Carbohydrates and mucin-likeficity’79
moleculesThe ’three step’ process discussed above is
oversimplified and refinements to this model Selectins appear to recognize a sialylated carbo-
are required. Firstly, selectins actually mediate hydrate determinant on their counterreceptors.
two steps, initial tethering to the vessel wall The carbohydrate ligands for L- and P-selectin
and rolling, which can be distinguished for E- are O-linked to specific mucin-like molecules.
selectin (see Selectins) by dependence on differ- Mucins are serine- and threonine-rich proteins
ent classes of neutrophil ligands. Thus, some that are heavily O-glycosylated and have an
selectin-ligand combinations may be important extended structure.
in tethering and others in rolling. Leukocytes in
the bloodstream travel about 1 000 microns per Chemoattractants
second, much too fast for them to sense the
chemotactic factor emanating from a site of Chemoattractants are important in activation of
damage or infection. The selectins and their integrin adhesiveness and in directing the migra-
carbohydrate ligands have been found to med- tion of leukocytes. In chemotaxis, cells move in
iate the initial decelerating event, which is the direction of increasing concentration of a
characterized by the tethering and subsequent chemoattractant, which typically is a soluble
rolling that allows the leukocyte to test the molecule that can diffuse away from the site of
microenvironment adjacent to the inflammatory its production, where its concentration is high-
site.77 est.84 Leukocytes, which can sense a difference
Secondly, the steps are overlapping, rather of 1% in chemokine concentration across their
than strictly sequential. Although L-selectin is diameter, move steadily in the direction of the
shed from neutrophils soon after activation, chemoattractant. As mentioned earlier, the clas-
ligands for E-selectin remains on the neutrophil sical leukocyte chemoattractant acts broadly, on
surface, and thus interactions with E-selectin neutrophils, eosinophils, basophils, and mono-
will probably persist until transendothelial mb cytes, whereas the chemokines have specificity
gration is completed.79 for leukocyte subsets.79 This suggests that the
chemokines may be centrally involved in speci-
fic (transendothelial) migration of leukocyteSelectins
subsets. The CC chemokine RANTES is a
The selectins or lectin cellular adhesion mole- chemoattractant for memory T cells in vitro
cules, include the molecules L-selectin, P-selec- and human MIP-lcz and MIP-1[3 have been found
tin and E-selectin. They are transmembrane to be chemoattractant for distinct subpopula-
molecules, with a number of extracellular do- tions of lymphocytes including naive T-cells and
mains homologous to those seen in the comple- B-cells. The CC chemokines MCP-1 and C10 are
9ment receptors. The extracellular region also thought to induce T cell migration just as
has a domain related to the EGF-receptor some of the CXC chemokines e.g. IL-8 and IP-
(epidermal growth factor) and a N-terminal 10. The C chemokine, lymphotactin, also shows
domain which has lectin-like properties (i.e. it T-lymphocyte chemoattractant activity. Further-
binds to carbohydrate residues).8 L-selectin is more, some of the CC chemokines are potent
expressed on all circulating leukocytes, except promigratory signals for basophils and eosino-
for a subpopulation of memory lymphocytes. P- phils, findings which may be relevant to the
selectin is stored preformed in the Weibel- understanding of allergy and asthma.9
Palade bodies of endothelial cells and the (z It has long been discussed whether chemoat-
granules of platelets. In response to mediators tractants can act in the blood stream, where
of acute inflammation, such as thrombin or they would be rapidly diluted and swept down-
histamine, P-selectin is rapidly mobilized to the stream by bloodflow. Tethering and rolling of
plasma membrane to bind neutrophils and leukocytes through selectins will enhance ex-
monocytes. E-selectin is induced on vascular posure to chemoattractants by prolonging leu-
endothelial cells by cytokines such as IL-1, kocyte contact with the vessel wall. However,
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retention of chemoattractants at their site of Immunoglobulin superfamily
production by noncovalent interactions with members on endothelium as integrin
molecules on the vessel wall and within the ligands
inflammatory site may also be important. Hepar- Several different immunoglobulin superfamilyin binding sites on chemokines provide a
mechanism for retention in the extracellular (IgSF) members, expressed on endothelium
matrix, enhancement of concentration gradi- bind to integrins expressed on leukocytes.ICAM-1 (intercellular adhesion molecule 1),
ents, and perhaps presentation of chemokines ICAM-2, and ICAM-3 are products of distinct
on the endothelium to circulating leukocytes,a5
and homologous genes and were all initially
identified by their ability to interact with LFA-1.
Induction of ICAM-1 on endothelium and otherChemoattractant receptors
cells by inflammatory cytokines may increase
Leukocyte chemoattractant receptors have mul- cell-cell interactions and leukocyte extravasa-
tiple functions. They do not only direct migra- tion at inflammatory sites, whereas constitutive
tion, but also activate integrin adhesiveness and expression of ICAM-2 may be important for
stimulate degranulation, shape change, actin leukocyte trafficking in uninflamed tissues, as in
polymerization, and the respiratory burst79 As lymphocyte recirculation. Vascular cell adhesion
mentioned earlier, chemoattractant receptors molecule 1 (VCAM-1) is inducible by cytokines
are G-protein coupled receptors that span the on endothelial cells and on a more restricted
membrane seven times. Neutrophils and lym- subset of nonvascular cells than ICAM-1.79
phocytes express G(zi2 and Gczi3 subunits. The
G(x subunits of the tzi class are ADP-ribosylated
and irreversible inactivated by pertussis toxin. The role of chemokines in
All of the biological effects of leukocyte che- chemotaxis
moattractants are inhibited by pertussis toxin.
Coupling through Gai subunits has been con-
firmed by reconstitution in. transfected cells.79
Integrins
The selective chemoattractant activities of the
chemokines make them ideal candidates to play
a key role in the ’sorting’ problem of leukocyte
trafficking, i.e. getting the correct subpopula-
tion of cells to migrate into the tissues. The
chemokines may be even more ideally adapted
Integrins are perhaps the most versatile of the to directing leukocyte trafficking, because some
several adhesion molecules. They are integral of these proteins can also promote cell subtype
membrane proteins that help to bind cells to specific adhesion.39 Taub and colleagues, have
the extracellular matrix. Each member of this reported that both MIP-la and-1, as well as
large family of molecules consists of two non- RANTES and ,IP-10, increase the adhesive
covalently bound polypeptides ((, and [3), both properties of the cells for which they are
39of which traverse the membrane. They fall into chemoattractant. However, if chemokines play
three main sub-families, depending on whether an important part in attracting rolling leuko-
they have a [31 chain, a {32 chain or a {33 chain, cytes to the inflammatory site, then it is likely
Recent discoveries suggest that the assortment that they would form a chemotactic gradient;
of a chains with chains is not quite as precise however, until a few years ago it was unclear
as originally thought. Broadly speaking the [31- how they could form an appropriate gradient
integrins are involved in binding of cells to under the conditions of vascular flow. An initial
extracellular matrix, the [32-integrins are in- clue to the way in which a chemokine gradient
volved in leukocyte adhesion to endothelium or could be formed came from examination of the
to other immune cells, and the [33-integrins are chemokine sequences. All of the chemokines
involved in the interactions of platelets and have positively charged domains capable of
neutrophils at inflammatory sites or sites of binding the highly negatively charged carbo-
vascular damage. Integrin adhesiveness can be hydrates of proteoglycans, and a number of
rapidly regulated by the cells on which they are different chemokines have been shown to be
expressed. Thus far, the best candidates for capable of binding immobilized carbohyadrates,
activation of integrin adhesiveness within the such as heparin sulphate77 Tanaka et al. 5 have
vasculature are chemoattractants. It is likely that provided strong evidence for an association
the increased adhesiveness of integrins, such as between MIP-I and glycosaminoglycans
Mac-1 and lymphocyte function-associated anti- (GAGs) on the proteoglycan CD44 (Fig. 5). They
gen 1 (LFA-1), is due to a conformational change have shown that MIP-I is present on lymph
in the integrins upon activation, node endothelium and that immobilized MIP-I
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FIG. 5. A hypothetical, multistep model of the extravasation of specific leukocyte subsets near a site of infection. The
sequential steps provide the traffic signals that regulate leukocyte localization in the vasculature. Lymphokines produced in
response to the pathogen induce changes in the epithelium, including the formation of a gradient of specific chemokines:
the gradient may be generated by local production of the chemokines by endothelial cells and their electrostatic attachment
to glycosaminoglycan carbohydrates on proteoglycans as CD44.77’79
induces binding of T cells to VCAM-1 in vitro.
In these experiments, MIP-I was immobilized
by binding to proteoglycan: a conjugate of
heparin with bovine serum albumin (BSA) and
cellular proteoglycan CD44 were both effective.
Tanaka et al. propose that MIP-I and other
cytokines with glycosaminoglycan-binding sites
will bind to and be presented by endothelial
proteoglycans to trigger adhesion selectivity not
only of lymphocyte subsets, but also for other
cell types.85
Evidence has now accumulated that chemo-
kines may generally form chemical gradients in
an immobilized phase via electrostatic inter-
actions with negatively charged proteoglycans.39
As a result, it might be convenient to think of
chemokines as requiring a scaffolding or pre-
sentation molecule in order to interact properly
with their related receptor (Fig. 5). This would
be an appropriate strategy in vivo, as unless the
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chemotactic gradient was preserved in a solid
phase, normal conditions of blood flow would
wash away any chemoattractant, and a constant
replenishment would be required at the source.
As the chemoattractant can now be considered
as being sequestered and maintained by stable
components of the extracellular matrix, a single
release of chemokine (as might occur during
platelet degranulation) might be sufficient to
initiate the inflammatory cascade. The inflam-
matory response could then be ’fine tuned’ as
each cell which traffics through a vessel could
leave its own signals bound in solid phase.
The model of chemokine involvement in
leukocyte trafficking can now be summarized as
follows:
(a) a chemokine, sequestered in solid phase on
the endothelial cell surface, is presented as
a signal to trap a specific type of leukocyte
Chemokines and their role in inflammations
as the cell is undergoing selectin-mediated from studies of lymphocyte and neutrophil
rolling along the endothelium; TEM. One important difference between eosino-
(b) the leukocyte is selectively activated by the phils and neutrophils is that when the CD18
chemokine so that the cell stops rolling and molecule is dysfunctional or absent (as e.g. is
becomes firmly adhered; the case in leukocyte adhesion deficiency dis-
(c) the adhered leukocyte ’crawls’ along the ease) neutrophils do not migrate outside of the
chemotactic gradient formed by the chemo- vasculature into skin and most other tissues; in
kines on the endothelium; these patients, eosinophils are still capable of
(d) the leukocyte undergoes diapedesis and migrating. Ebisawa et aL86 speculate that the
migrates into the tissue space, while still VLA-4/VCAM-1 system may operate as a failsafe
responding to a chemotactic gradient, mechanism for TEM in cases in which the
CD18/ICAM-1 pathway is not functional. It is
In the following sections we will discuss certain also possible that the VLA-4/VCAM-1 pathway,
specific chemokines in relation to asthma and which is operative in monocytes and lympho-
inflammation, cytes as well, may be utilized during stimulation
of the CC chemokine receptor when leukocytes
The Effect of RANTES on the are migrating across activated endothelium in
Eosinophil Transendothelial vivo.Asthmatic individuals have elevated levels ofMigration (TEM)
eosinophil-priming cytokines in their circulation
Studies using an in vitro model of TEM utilizing as well as in the airways; allergen challenge
eosinophils,6 showed that eosinophil TEM is in causes dramatic increases in levels of these
certain ways similar to that of neutrophils. For cytokines. Furthermore, eosinophils of asth-
example, activation of endothelial cells with IL- matic subjects display evidence of having been
1 or TNF can significantly increase eosinophil subject to priming in vivo. Although the effect
TEM. In contrast, a number of differences of RANTES on BAL eosinophils has not been
between eosinophil TEM and that of neutro- assessed directly, one may speculate that the
phils or other leukocytes have also been ob- synergy between priming cytokine and RANTES
served. Notable among these is the observation chemotaxis would be expected in these BAL
that eosinophil active cytokines, including IL-3, eosinophils. It has recently been shown that
IL-5, and GM-CSF, can profoundly potentiate the higher levels of RANTES are found in the BAL
TEM of eosinophils, while having no effect on fluid of asthmatic individuals than in normal
neutrophils. These cytokines are not acting as individuals. Dahinden et aL87 reported that
chemoattractants as they need not be present MCP-3 is also chemotactic for eosinophils.
during the TEM assay. Analysis of a host of Although it is approximately one order of
chemokine molecules has revealed that espe- magnitude less potent than RANTES in activat-
cially RANTES is an effective eosinophil chemo- ing eosinophils, MCP-3 must also be considered
attractant which has no migration-stimulating as having potential relevance to eosinophilic
properties for neutrophils. The chemokines responses in vivo.87
investigated were IL-8, PF-4, B-TG, yIP-lO, MCAF,
MIP-Iz, RANTES, MIP-I and 1-309. In addition, The Effect of IVlCP-3 oninjection of human RANTES into dog skin has Eosinophils and Basophilsbeen shown to induce a profound eosinophilic
infiltrate.32 The effect of RANTES was concen- In basophils, MCP-3, MCP-1, RANTES and MIP-
tration-dependent, was inhibited by antibodies lz all induced cytosolic free-calcium concentra-
against the CD18 adhesion complex on eosino- tion changes and, with different efficacies,
phils, and was greatly potentiated by exposure chemotaxis (RANTES MCP-3 >> MCP-1 >
of the eosinophils to the priming cytokine, IL-5. MIP-Iz), histamine release (MCP-1 MCP-3 >>
Interestingly, the chemokine RANTES did not RANTES > MIP-Iz), and LTC4 formation after
cause changes in eosinophil adhesion molecule IL-3 pretreatment (MCP-1 MCP-3 >> RANTES
expression, nor did it induce any apparent > MIP-Iz).7 Thus, MCP-3 is as effective as
increase in adhesion of eosinophils to either MCP-1 as an inducer of mediator release, and as
resting endothelial cells or cultured endothelial effective as RANTES as a stimulus of basophil
cells activated with IL-1.6 Previous studies migration. In contrast to MCP-1, MCP-3 is also a
showed that CD18 and its endothelial counter- stimulus for eosinophils, and induces tea2+]
ligand, ICAM-1, are quite important in TEM of changes and chemotaxis as effectively as
eosinophils across IL-l-activated endothelial RANTES.
cells. Similar conclusions have been derived MCP-3 has been reported to interact with
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several CC chemokine receptors, which can be fluid collected 3 h after aerosol allergen chal-
simultaneously or selectively expressed on leu- lenge of actively sensitized guinea-pigs. The
kocyte subpopulations.88 Studies based on de- HPLC fraction that showed eosinophil chemoat-
sensitization of the calcium flux predicted at tractant activity, showed no permeability-
least three types of receptors: (1) MCP-1 increasing activity. In vitro, eotaxin induced
receptor on monocytes and basophils, (2) increases in [Ca2+]i and induced a dose-related
selective RANTES receptor on basophils and eosinophil aggregation. In vivo, eotaxin in-
eosinophils, and (3) selective MIP-I(z receptor duced substantial eosinophil accumulation
on basophils, eosinophils, and neutrophils, when injected in the skin of naive guinea-pigs.
Results obtained from binding studies using No significant changes in the number of neutro-
[125I]MCP-1 and [125I]MIP-lc on monocytes phils or mononuclear cells were observed.91
suggested that MCP-3 may also interact with Eotaxin consists of 73 amino acids and is a
CC CKR1, the MIP-I(z/RANTES receptor. Ben- member of the CC branch of chemokines.
Baruch et aL88 demonstrated that CC CKR1 Surprisingly, the greatest homology is with hu-
exhibited even higher binding affinity for man MCP-1 (53%), MCP-2 (54%) and MCP-3
[125I]MCP-3 than for [25I]RANTES and (51%) with respect to the amino acid sequence.
[125I]MIP-lc. Thus, MCP-3 may, because of its As mentioned earlier MCP-1 has been reported
powerful stimulus of chemotaxis for both to be inactive on human eosinophils. Homology
eosinophils and basophils, and of histamine with other human CC chemokines is rather
and LTC4 release from basophils, play an low: MIP-I (37%), MIP-lcz (31%), and RANTES
important role in asthma. MCP-1 might be (26%). The latter two proteins have been shown
involved as well, as it is a chemoattractant for, to be potent eosinophil activators in vitro,
and stimulates histamine and LTC4 release whereas MIP-I activates lymphocytes in vitro,
from, basophils very effectively. Moreover, but apparently not eosinophils.6 Due to the
MCP-1 is also found in the bronchial epithelium high homology with MCP-3 and the fact that
of asthmatic patients.89 To date the role of MCP-3 and eotaxin are both causing eosinophil
MCP-2 has not been elucidated, but as it is not chemotaxis, it was first thought that guinea-pig
very potent in chemotaxis and activation, it is eotaxin is the homologue of human MCP-3.
thought not to play a critical role in diseases This, however, seems unlikely since eotaxin
such as asthma, does not share the chemotactic activity with
MCP-3 on other cells than eosinophils.
Rothenberg et al.9 have identified a murineEotaxin
eotaxin, and the structural similarities between
Asthma is often characterized by tissue re- murine (mouse) and guinea-pig eotaxin indicate
cruitment of predominantly eosinophils; che- that both are more closely related to each other
mokines acting on eosinophils include certain than to other members of the CC family of
CC chemokines, e.g. MCP-2, MCP-3, RANTES chemokines. For example, each protein con-
and MIP-lc. The CXC chemokine IL-8 is also tains several unique features including a gap in
chemoattractive for cytokine-primed eosino- the alignment with the MCPs of two amino
phils. However, none of these chemoattractive acids near the N-terminal end of the protein
molecules are eosinophil-specific and their rela- and the conservation of basic amino acids near
tive importance in selected diseases and experi- the C-terminal end that distinguish it from other
mental animal models for allergy remains CC chemokines. It is also noteworthy that the
unclear.9 In contrast to the factors discussed so N-terminal end of MCP-1, including the N-
far, eotaxin, a recently described CC chemo- terminal Gln, which has been shown to be
kine, has been proposed as an eosinophil critical for monocyte activity, is replaced by a
chemoattractant in a guinea-pig model of aller- His in both routine and guinea-pig eotaxin.
66 91gic airway inflammation. Eotaxin appears to These comparisons suggest that eotaxin is a
be unique among the chemokines since it distinct cytokine and not a homologue of a
causes the selective infiltration of eosinophils known member of the family.
only, when injected into the skin and when
directly administered to the lungs of naive Eotaxin mRNA expression in different
guinea-pigs. In experiments described by
Rothenberg et aL9 migrating cells (induced. by organs
eotaxin) were > 95% eosinophils. As would be expected, eotaxin mRNA is con-
In 1993, Griffiths-Johnson and colleagues91 stitutively expressed in mucosal tissues that
reported the purification of a novel chemokine, normally contain eosinophils (skin, lung, and
’eotaxin’, from bronchoalveolar lavage (BAL) intestinal tract).9 Nonetheless, expression of
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murine eotaxin is also seen in thymus, lymph Eosinophils contain an armory of chemicals
node, and muscle where resident eosinophils necessary for killing parasites. These chemicals
are rare. This pattern of mRNA tissue distribu- have been implicated in the damage to airway
tion is similar to that seen in guinea-pigs, epithelium that occurs in asthma and may relate
although mice have higher expression in the to the observed changes in airway function.
thymus and skin and guinea-pigs have higher Rothenberg et al.92 suggest that eotaxin should
expression in the lung.92 Northern blot analyses be considered as a potentially important endo-
of total RNA isolated from different guinea-pig genous mediator of eosinophil accumulation in
tissue samples revealed easily detectable consti- vivo. In particular, eotaxin and related mole-
tutive expression of eotaxin in the lung. Lower cules may be involved in both eosinophil
levels were detectable in the intestines, sto- accumulation and in chronic structural changes
mach, heart, thymus, spleen, liver, testes, and in the asthmatic lung.
kidney. In addition, no RNA was detectable in Subsequent to the discovery of guinea pig
the brain, bone marrow, or skin.92 The finding and murine eotaxin, a research team at Leuko-
of constitutive eotaxin mRNA in mucosal tissues Site (Cambridge, MA) very recently identified
where eosinophils are predominantly located human eotaxin, examined its chemotactic activ-
(lung and intestines), suggests that eotaxin may ity and characterized its binding to an eosino-
play a role in the normal tissue homing and phil receptor, distinct from the CC chemokine
turnover of eosinophils, receptors CC CKR1 (MIP-Iz/RANTES receptor)
The unexpected expression of eotaxin mRNA and CC CKR2A,B (MCP-1 receptor). Human
in lymphoid tissue and muscle suggests that eotaxin manifested a powerful and selective
eotaxin may effect other cell types, because chemotactic activity towards eosinophils in
eosinophils are normally not present in these both in vitro and in vivo assays. The fact that
tissues, and that eotaxin might therefore have a the chemokines are a ’hot topic’ is shown by
more widespread function. The expression in the unusual situation that human eotaxin was
the thymus and lymph node suggests that already available on the market9 before its
eotaxin may direct lymphocyte homing.9 identification and functional characteristics had
Although the eotaxin gene is expressed at been published. It was only at the beginning of
relatively high levels in the lungs of healthy 1996 that the cloning and functional charac-
guinea-pigs without airway inflammation, the terization of human eotaxin was reported by
chemotactic activity ascribed to eotaxin has Ponath et al.94
been reported to be undetectable in the broncho-
alveolar fluid of non-antigen-challenged guinea-
pigs. Thus, eotaxin mRNA is constitutively ex- CC Chemokines as a Target forpressed at easily detectable levels in the lung, New Drug Therapy in Asthma
when eotaxin activity is still undetectable. After
antigen challenge, eotaxin gene expression in To date, no studies concerning strategies antag-
the lung is further increased during the early onizing chemokines for asthma therapy are
part of the late phase response. Thus, up- available. The investigations on chemokines so
regulation of gene expression, and not constitu- far, have mainly focused on the discovery of
tire expression, is associated with the pathogen- new chemokines and their receptors, and the
esis of airway disease.92 The up-regulation of understanding of their function. It has been
eotaxin mRNA as well as protein after allergen reported that glucocorticoids inhibited the
challenge shows that the response is, at least to epithelial expression of RANTES.95
a large extent, at the level of transcription Glucocorticoids have been used in therapy
rather than translation of the existing mRNA, for many years and they are currently the first
although the factor responsible for this up- choice treatment for asthmatic patients. These
regulation is unknown, steroids however, have many functions e.g.
Eotaxin is likely to act in parallel with other inhibition of the production and activity of
cytokines generated during the late phase re- many cytokines, reduced generation of eico-
sponse. For example, IL-5 can prime eosinophils sanoids and PAE reduced cyclooxygenase-2 ex-
to respond to another CC chemokine, RANTES, pression, increased 132 expression, reduced
and can promote eosinophil tissue survival and vasodilatation and decreased fluid exudation. As
activation.92 The CC chemokines have also been a result of this wide variety of functions,
implicated in wound healing which may be corticosteroids can cause severe side effects e.g.
important in the subepithelial basement mem- osteoporosis, suppression of endogenous gluco-
brahe fibrosis that is a prominent feature of the corticoid synthesis, poor wound healing, super-
asthmatic lung. infections, tendency to hyperglycaemia and
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thinning of the skin.96 These undesired effects
can be reduced by local application. In severe
asthma however, the steroids are administered
systemically.
New therapies are the development of drugs
that could aim at a selective inhibition of the
migration of leukocytes involved in a specific
disease. As discussed in this review, chemokines
are thought to play a major role in the recruit-
ment of these leukocytes and therefore, drugs
that modify the production and/or function of
these chemokines might be worth investigating.
In asthma the attention should be focused on
the chemokines that predominantly cause the
recruitment of eosinophils. Modifications are
possible at several levels. Firstly, specific anti-
bodies can be developed. For IL-8 there is
already an antibody available which selectively
blocks the IL-8 function. Antibodies for eotaxin
and maybe also for RANTES and MCP-3 may be
successful. However, the use of antibodies
might in practice not be effective, due to typical
pharmaceutical constraints. Secondly, the
development of antagonists for the receptors
involved, should be considered. There are
probably several different chemokines involved,
all contributing to some degree. Thus, antago-
nizing the promiscuous receptors may therefore
be the most effective. Preliminary results were
obtained by Wells et al.6 They identified a
series of variants of the CC chemokine RANTES
that are potent receptor antagonists. These
molecules are active in the low nanomolar
range, and are able to block CC chemokine
effects on purified human cells in vitro.
Whether these antagonists will also be able to
block CC chemokines effects in vivo remains to
be elucidated. Thirdly, the production of che-
mokines can be inhibited by the use of anti-
sense RNA. In this way translation of the mRNA
is prevented and thus the production of the
target chemokine. Depending on the homology
between the nucleotide sequences of different
chemokines, this method might be very selec-
tive. From these three options, the development
of chemokine antagonists seems the most pro-
mising, as they have already been shown to be
effective in vitro. Furthermore, their use in
practice is not limited due to typical constraints,
as is the case for antibodies and peptidic
compounds.
References
1. Voss H-P. Long-acting 2-adrenoceptor agonists in asthma: molecular
pharmacological aspects. Thesis, Vrije Universiteit Amsterdam, 1994.
2. Barnes PJ. Anti-inflammatory therapy. Annu Rev Med 1993; 44: 229-
242.
3. Virchow JC Jr, Kroegel C, Walker C, Matthys H. Cellular and
immunological markers of allergic and intrinsic bronchial asthma. Lung
1994; 172: 313-334.
4. Shelhamer JH, Levine SJ, Wu T, Jacoby DB, Kaliner MA, Rennard SI.
NIH conference. Airway inflammation. Ann Intern Med 1995; 123:
288-304.
5. Rang HP, Dale MM, Ritter JM, eds. The respiratory system. In:
Pharmacology. New York: Churchill Livingstone, 1995; 351-366.
6. Linssen M. Animal models for the selection of anti-inflammatory
compounds for the treatment of bronchial hyperreactivity in asthma.
Thesis, Vrije Universiteit Amsterdam, 1990.
7. Kay AB, Corrigan CJ. Eosinophils and neutrophils. Br Med Bull 1992;
48: 51-64.
8. Barnes PJ, ed. Asthma. Vo148. London: Churchill Livingstone, 1992.
9. Doelman CJA. Reactive oxygen species and airway hyperreactivity.
Thesis, Vrije Universiteit Amsterdam, 1991.
10. Kirby JG, Hargreave FE, Gleich CJ, O’Byrne PM. Bronchoalveolar cell
profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis
1987; 136: 379-383.
11. Wardlaw AJ, Dunnete S, Gleich GJ, Collins JV, Kay AB. Eosinophils and
mast cells in bronchoalveolar lavage in subjects with mild asthma. Am
Rev Respir Dis 1988; 137: 62-69.
12. delroth E, Rosenhall L, Johansson S, Linden M, Venge P. Inflamma-
tory cells and eosinophilic activity in asthmatics investigated by
bronchoalveolar lavage: the effects of anti-asthmatic treatment with
budesonide or terbutaline. Am Rev Respir Dis 1990; 142: 91-99.
13. Jeffrey PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial
biopsies in asthma. An ultrastructural, quantitative study and correla-
tion with hyperreactivity. Am Rev Respir Dis 1989; 140: 1745-1753.
14. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the
bronchi in mild asthma and after bronchial provocation. Am Rev
Respir Dis 1989; 139: 806-817.
15. O’Byrne PM. What is asthma? An update on the mechanisms. J Invest
Allergol Clin Immunol 1995; 5: 6-11.
16. Azzawi M, Bradley B, Jeffery PK, Frew AJ, Wardlaw AJ, Knowles G,
Assoufi B, Collins JV, Durham S, Kay AB. Identification of activated T-
lymphocytes and eosinophils in bronchial biopsies in stable atopic
asthma. Am Rev Respir Dis 1990; 142: 1407-1413.
17. Bochner BS, Undem BJ, Lichtenstein LM. Immunological aspects of
allergic asthma. Annu Rev Immunol 1994; 12: 295-335.
18. Dale HH, Laidlaw PP. The physiological action of
-imida-
zolylethylamine. J Physiol (London) 1910; 41:318-344.
19. Schwartz L, Huff T. Biology of mast cells and basophils. In: Middleton
E, Reed CE, Ellis EE Adkinson Jr NE Yunginger JW, Busse W, eds.
Allergy Principles and Practice. St Louis: Mosby, 1993; 135-168.
20. Henocq E, Vargaftig BB. Accumulation of eosinophils in response to
intracutaneous PAF-acether and allergen in man. Lancet 1986; 2:
1378-1379.
21. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein
induces airway constriction and airway hyperresponsiveness in
primates. J Clin Invest 1991; 87: 1470--1473.
22. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic
cytokines: CXC and CC chemokines. Adv Immunol 1994; 55: 97-179.
23. Strieter RM, Koch AE, Antony VB, Fick Jr RB, Stradiford TJ, Kunkel SL.
The immunopathology of chemotactic cytokines: the role of interleu-
kin-8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994;
123: 183-197.
24. Horuk R. Molecular properties of the chemokine receptor family. TIPS
1994; 15: 159-165.
25. Pruzanski W, Vadas P, eds. Novel Molecular Approaches to Anti-
inflammatory Theory. Vol. 46. Basel: Birkhiuser Verlag, 1995; 1-22.
26. Boyden Jr SE. The chemotactic effects of mixtures of antibody and
antigen on polymorphonuclear leukocytes. J Exp Med 1962; 115: 453-
466.
27. Murphy PM. The molecular biology of leukocyte chemoattractant
receptors. Annu Rev Immunol 1994; 12: 593-633.
28. Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K. Properties
of the novel proinflammatory supergene ’intercrine’ cytokine family.
Annu Rev lmmunol 1991; 9: 617-648.
29. Luster AS, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally
regulates an early-response gene containing homology to platelet
proteins. Nature 1985; 315: 672-676.
30. Yoshimura TK, Matsushima K, Tanaka S, Robinson EA, Appella E,
Oppenheim JJ, Leonard EJ. Purification of a human monocyte-derived
neutrophil chemotactic factor that shares sequence homology with
other host defense cytokines. Proc Natl Acad Sci USA 1987; 84: 9233-
9237.
31. Yoshimura TK, Matsushima K, Oppenheim JJ, Leonard EJ. Neutrophil
chemotactic factor produced by lipopolysaccharide (LPS)-stimulated
human blood mononuclear leukocytes: partial characterization and
separation from interleukin (IL 1). J Immunol 1987; 139: 788-793.
32. Meurer R, Riper GV, Feeney W, Cunningham P, Hora Jr D, Springer MS,
Maclntyre DE, Rosen H. Formation of eosinophilic and monocytic
intradermal inflammatory sites in the dog by injection of human
RANTES but not human monocyte chemoattractant protein 1, human
macrophage inflammatory protein 1, of human interleukin 8. J Exp
Med 1993; 178: 1913-1921.
414 Mediators of Inflammation Vol 5 1996
Chemokines and their role in inflammations
33. Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA,
Jenkins NA, Copeland NG, Bazan JF, Moore KW, Schall TJ, Zlotnik A.
Lymphotactin: a cytokine that represents new class of chemokine.
Science 1994; 266: 1395-1399.
34. Kelner G, Zlotnik A. Cytokine production profile of early thymocytes
and the characterization of a new class of chemokine. J Leuk Biol
1995; 57: 778-781.
35. Kennedy J, Kelner GS, Kleyensteuber S, Schall TJ, Weiss MC, Yssel H,
Schneider PV, Cocks BG, Bacon KB, Zlotnik A. Molecular cloning and
functional characterization of human lymphotactin. J Immunol 1995;
155: 203-209.
36. Clark-Lewis I, Kim K-S, Rajarathnam K, Gong J-H, Dewald B, Moser B,
Baggiolini M, Sykes BD. Structure-activity relationships of chemokines.
J Leuk Biol 1995; 57: 703-711.
37. Farber JM. HuMIG: a new member of the chemokine family of
cytokines. Biochem Biophys Res Comm 1993; 192: 223-230.
38. Proost P, De Wolf-Peeters C, Conings R, Opdenakker G, Billiau A, Van
Damme J. Identification of a novel granulocyte chemotactic protein
(GCP-1) from human tumor cells: in vitro and in vivo comparison with
natural forms of GROa, IP-10, and IL-8. J Immunol 1993; 150: 1000-
1010.
39. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and
inflammation. Curt Opin Immunol 1994; 6: 865-873.
40. Chaudhuri A, Polyakova J, Zbrzezna V, Williams K, Gulati S, Pogo AO.
Cloning of glycoprotein D cDNA which encodes the major subunit of
the Duffy blood group system and the receptor for the plasmodium
vivax malaria parasite. Proc Natl Acad Sci USA 1993; 90: 10793-
10797.
41. Horuk R, Colby I1, Darbonne WC, Schall TJ, Neote K. The human
erythrocyte inflammatory peptide (chemokine) receptor. Biochemical
characterization, solubilization, and development of binding assay for
the soluble receptor. Biochemistry 1993; 32: 5733-5738.
42. Neote K, DiGregorio D, Mak JY, Horuk R, Schall T. Molecular cloning,
functional expression, and signaling characteristics of C-C chemokine
receptor. Cell 1993; 72: 415-425.
43. Schall TJ, Stein B, Gorgone G, Bacon KB. Cytomegalovirus encodes a
functional receptor for C-C chemokines. In: McFadden G, ed. Virocep-
tors, Virokines and Related Immune Modulators Encoded by DNA
Viruses. RG Landes; Chapter 12.
44. Ahuja SK, Murphy PM. Molecular piracy of mammalian interleukin-8
receptor type B by herpesvirus saimiri. J Biol Chem 1993; 268:
20691-20694.
45. Moser B, Schumacher C, von Tscharner V, Clark-Lewis I, Baggiolini M.
Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory
activity interact with neutrophil-activating peptide 1/interleukin-8
receptors on human neutrophils. J Biol Chem 1991; 266: 10666-
10671.
46. Schumacher C, Clark-Lewis I, Baggiolini M, Moser B. High-and low-
affinity binding of GRO and neutrophil-activating peptide 2 to
interleukin-8 receptors on human neutrophils. Proc Natl Acad Sci USA
1992; 89: 10542-10546.
47. Baggiolini M, Loetscher P, Moser B. Interleukin-8 and the chemokine
family. IntJImmunopharm 1995; 17: 103-108.
48. Kelvin DJ, Michiel DF, Johnston JA, Lloyd AR, Sprenger H, Oppenheim
JJ, Wang J-M. Chemokines and serpentines: the molecular biology of
chemokine receptors. J Leuk Biol 1993; 54: 604-612.
49. Samanta AK, Oppenheim JJ, Matsushima T. Interleukin 8 (monocyte-
derived neutrophil chemotactic factor) dynamically regulates its own
receptor expression on human neutrophils. J Biol Chem 1990; 265:
183.
50. Besemer J, Hujber A, Kuhn B. Specific binding, internalization, and
degradation of human neutrophil activating factor by human polymor-
phonuclear leukocytes. J Biol Chem 1989; 264: 17409.
51. Grob PM, David E, Warren TC, DeLeon RP, Farina PR, Homon CA.
Characterization of a receptor for human monocyte-derived neutrophil
chemotactic factor/interleukin-8. J Biol Chem 1990; 265:8311.
52. Chuntharapai A, Kim KJ. Regulation of the expression of IL-8 receptor
A/B by IL-8: possible functions of each receptor. J Immunol 1995;
155: 2587-2594.
53. Chuntharapai A, Lee J, Hebert C, Kim KJ. Monoclonal antibodies detect
different distribution patterns of IL-8 receptor A and IL-8 receptor B on
human peripheral blood leukocytes. J Immunol 1994; 153: 5682.
54. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI.
Characterization of two high affinity human interleukin-8 receptors.
J Biol Chem 1992; 267: 16283.
55. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Both
interleukin-8 receptors independently mediate chemotaxis. Jurkat cells
transfected with IL-SR1 of IL-SR2 migrate in response to IL-8, GROcz
and NAP-2. FEBS Lett 1994; 341: 187.
56. Hdbert CA, Chuntharapai A, Smith M, Colby T, Kim J, Horuk R. Partial
functional mapping of the human interleukin-8 type A receptor. J Biol
Chem 1993; 268: 18549-18553.
57. Clark-Lewis I, Schumacher C, Baggiolini M, Moser B. Structure-activity
relationships of interleukin-8 determined using chemically synthesized
analogs. Critical role for NH2 terminal residues and evidence for
uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding
activities. J Biol Chem 1991; 266: 23128-23134.
58. Hdbert CA, Vitangcol RV, Baker JB. Scanning mutagenesis of interleu-
kin-8 identifies cluster of residues required for receptor binding.
J Biol Chem 1991; 266: 18989-18994.
59. Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC. Sequence
alignment of the G-protein coupled receptor family. DNA Cell Biol
1992; 11: 1-20.
60. Gao J-L, Kuhns DB, Tiffany HL, McDermott D, Li X, Francke U, Murphy
PM. Structure and functional expression of the human macrophage
inflammatory protein lct/RANTES receptor. J Exp Med 1993; 177:
1421-1427.
61. Wang J-M, Sherry B, Fivash MJ, Kelvin DJ, Oppenheim JJ. Human
recombinant macrophage inflammatory protein-lz and
-
and mono-
cyte chemotactic and activating factor utilize common and unique
receptors on human monocytes. J Immuno11993; 150: 1-8.
62. Wang J-M, McVicar DW, Oppenheim JJ, Kelvin DJ. Identification of
RANTES receptor on human monocytic cells: competition for binding
and desensitization by homologous chemotactic cytokines. J Exp Med
1993; 177: 699-705.
63. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR.
Molecular cloning and functional expression of two monocyte
chemoattractant protein receptors reveals alternative splicing of the
carboxyl-terminal tails. Proc NatlAcad Sci USA 1994; 91: 2752-2756.
64. Combadiere C, Ahuja SK, Murphy PM. Cloning and functional expres-
sion of human eosinophil CC chemokine receptor. J Biol Chem
1995; 270: 16491-16494.
65. Combadiere C, Ahuja SK, Murphy PM. Cloning, chromosomal localiza-
tion, and RNA expression of a human beta chemokine receptor-like
gene. DNA Cell Biol 1995; 14: 673-680.
66. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty
NF, Truong O, Hsuan JJ, Williams TJ. Eotaxin: a potent eosinophil
chemoattractant cytokine detected in a guinea pig model for allergic
airways inflammation. J Exp Med 1994; 179: 881-887.
67. Raport CJ, Schweickart VL, Chantry D, Eddy Jr RL, Shows TB, Godiska
R, Gray PW. New members of the chemokines receptor gene family.
J Leuk Biol 1996; 59: 18-23.
68. Wells TNC, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM,
Chung C, Peitsch MC, Proudfoot AEI. Selectivity and antagonism of
chemokine receptors. J Leuk Biol 1996; 59: 53-60.
69. Neote K, Darbonne W, Ogez J, Horuk R, Schall TJ. Identification of a
promiscuous inflammatory peptide receptor on the surface of red
blood cells. J Biol Chem 1993; 268: 12247-12249.
70. Darbonne WC, Rice GC, Mohler MA, Apple T, Hbert CA, Valente AJ,
Baker JB. Red blood cells are a sink for interleukin 8, a leukocyte
chemotaxin. J Clin Invest 1991; 88:1362-1369.
71. Holmes WE, Lee J, Kuang W-J, Rice G, Wood WI. Structure and
functional expression of human interleukin-8 receptor. Science 1991;
253: 1278-1280.
72. Lusti-Narasimhan M, Power CA, Mlet B, Mouani S, Bacon KB, Mermod
J-J, Proudfoot AEI, Wells TNC. Mutation of Leu25 and Va127 introduces
CC chemokine activity into interleukin-8. J Biol Chem 1995; 270:
2716-2721.
73. Moser B, Dewald B, Barella L, Schumacher C, Baggiolini M. Interleukin-
8 antagonists generated by N-terminal modification. J Biol Chem 1993;
268: 7125.
74. Clark-Lewis I, Dewald B, Greiser T, Moser B, Baggiolini M. Platelet
factor 4 binds to interleukin-8 receptors and activates neutrophils
when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci
USA 1993; 90: 3574-3577.
75. Gong J-H, Clark-Lewis I. Antagonists of monocyte chemoattractant
protein-1 identified by modification of functionally critical NH2-
terminal residues. J Exp Med 1995; 181: 631-640.
76. Beall CJ, Mahajan S, Kolattukudy PE. Conversion of monocyte chemoat-
tractant protein-1 into a neutrophil attractant by substitution of two
amino acids. J Biol Chem 1992; 267: 3455-3459.
77. Lasky LA. Combinatorial mediators of inflammation? Curr Biol 1993; 3:
366-368.
78. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation.
Immunology Today 1994; 15: 127-133.
79. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte
emigration: the multistep paradigm. Cell 1994; 76: 301-314.
80. Butcher EC Leukocyte-endothelial cell recognition: three (or more)
steps to specificity and diversity. Cell 1991; 67: 1033-1036.
81. Laskey LA. Selectins: interpreters of cell-specific carbohydrate informa-
tion during inflammation. Science 1992; 258: 964-969.
82. Shimizu Y, Newman W, Tanaka Y. Lymphocyte interactions with
endothelial cells. Immunol Today 1992; 13:106-112.
83. Roitt I, Brostoff J, Male D. Immunology. 3rd edition. St Louis: Mosby,
1993.
84. Devreotes PN, Zigmond SH. Chemotaxis in eukaryotic cells: a focus on
leukocytes and Dictyostelium. Annu Rev Cell Biol 1988; 4: 649-686.
85. Tanaka Y, Adams DH, Huscher S, Hirano H, Siebenlist U, Shaw S. T-cell
adhesion induced by proteoglycan-immobilized cytokine MIP-I. Nat-
ure 1993; 361: 79-82.
86. Ebisawa M, Yamada T, Bickel C, Klunk D, Schleimer RP. Eosinophil
transendothelial migration induced by cytokines. III. Effect of the
Mediators of Inflammation Vol 5 1996 415
E A. A. van Acker, H-P. Voss and H. Timmerman
chemokine RANTES. J Immunol 1994; 153: 2153-2160.
87. Dahinden CA, Geiser T, Brunner T, Tscharner VV, Caput D, Ferrara P,
Minty A, Baggiolini M. Monocyte chemotactic protein 3 is a most
effective basophil- and eosinophil-activating chemokine. J Exp Med
1994; 179: 751-756.
88. Ben-Baruch A, Xu L, Young PR, Bengali K, Oppenheim JJ, Wang JM.
Monocyte chemotactic protein-3 (MCP-3) interacts with multiple
leukocyte receptors. J Biol Chem 1995; 270: 22123-22128.
89. Proost P, Wuyts A, Damme JV. Human monocyte chemotactic proteins-
2 and
-3: structural and functional comparison with MCP-1. J Leuk Biol
1996; 59: 67-74.
90. Rothenberg ME, Luster AD, Leder P. Murine eotaxin: an eosinophil
chemoattractant inducible in endothelial cells and in interleukin 4-
induced tumor suppression. Proc Natl Acad Sci USA 1995; 92: 8960-
8964.
91. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ. The
chemokine eotaxin, activates guinea-pig eosinophils in vitro and
causes their accumulation into the lung in vivo. Biochem Biophys Res
Comm 1993; 197: 1167-1172.
92. Rothenberg ME, Luster AD, Lilly CM, Drazen JM, Leder P. Constitutive
and allergen-induced expression of eotaxin mRNA in the guinea pig
lung. JExp Med 1995; 181: 1211-1216.
93. In: Sanver Techo, December 1995.
94. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith
H, Shi X, Gonzalo J-A, Newman W, Gutierrez-Ramos J-C, Mackay CR.
Cloning of the human eosinophil chemoattractant, eotaxin. J Clin
Invest 1996; 97: 604-612.
95. Stellato C, Beck LA, Gorgone GA, Proud D, Schall TJ, Ono SJ,
Lichtenstein LM, Schleimer RP. Expression of the chemokine RANTES
by a human bronchial epithelial cell line. Modulation by cytokines and
glucocorticoids. J Immuno11995; 155: 410-418.
96. Rang HP, Dale MM, Ritter JM. Anti-inflammatory and immunosuppres-
sant drugs. In: Pharmacology. New York: Churchill Livingstone, 1995.
ACKNOWLEDGEMENT. Dr E. Knol from the Centraal Laboratorium voor
Bloedtransfusiedienst (CLB) is gratefully acknowledged for the valuable
discussions during the preparation of the manuscript.
Received 7 October 1996;
accepted 8 October 1996
416 Mediators of Inflammation Vol 5 1996
